var title_f6_22_6496="TEE sinus venosus defect";
var content_f6_22_6496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73621/sinvetee_conv.mp4?title=TEE+sinus+venosus+defect\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinus venosus defect viewed by transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SVC: superior vena cava.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Brian Soriano.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6496=[""].join("\n");
var outline_f6_22_6496=null;
var title_f6_22_6497="Ciprofibrate: International drug information";
var content_f6_22_6497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofibrate: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Estaprol (AR);",
"     </li>",
"     <li>",
"      Hyperlipen (BE, CH, LU, NL);",
"     </li>",
"     <li>",
"      Lipanor (FR, HU, PT);",
"     </li>",
"     <li>",
"      Modalim (GB, NL);",
"     </li>",
"     <li>",
"      Oroxadin (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent, Fibric Acid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type IIa, IIb, III, and IV hyperlipidemias",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 100 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10357 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6497=[""].join("\n");
var outline_f6_22_6497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323557\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978317\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978320\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978316\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821202\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978319\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10357|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_22_6498="Immunofluorescence findings II";
var content_f6_22_6498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence findings in urticarial vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence of a biopsy specimen from a patient with urticarial vasculitis, demonstrating IgM deposits along the dermal-epidermal junction as well as involving blood vessel walls in the dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6498=[""].join("\n");
var outline_f6_22_6498=null;
var title_f6_22_6499="Dermatofibroma dermoscopy";
var content_f6_22_6499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic structures of dermatofibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral delicate pigment network with a central scar-like area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6499=[""].join("\n");
var outline_f6_22_6499=null;
var title_f6_22_6500="Rabies immune globulin (human): Drug information";
var content_f6_22_6500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rabies immune globulin (human): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/3/20531?source=see_link\">",
"    see \"Rabies immune globulin (human): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/29/41427?source=see_link\">",
"    see \"Rabies immune globulin (human): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HyperRAB&reg; S/D;",
"     </li>",
"     <li>",
"      Imogam&reg; Rabies-HT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      HyperRAB&reg; S/D;",
"     </li>",
"     <li>",
"      Imogam&reg; Rabies Pasteurized",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Immune Globulin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Postexposure prophylaxis:",
"     </b>",
"     Local wound infiltration: 20 units/kg in a single dose, RIG should always be administered as part of rabies vaccine regimen. If anatomically feasible, the full rabies immune globulin dose should be infiltrated around and into the wound(s); remaining volume should be administered I.M. at a site distant from the vaccine administration site. If rabies vaccine was initiated without rabies immune globulin, rabies immune globulin may be administered through the seventh day  after the administration of the first dose of the vaccine. Administration of RIG is not recommended after the seventh day post vaccine since an antibody response to the vaccine is expected during this time period.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Not for use in persons with a history of pre-exposure vaccination, history of postexposure prophylaxis, or previous vaccination with rabies vaccine and documentation of antibody response.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/29/41427?source=see_link\">",
"      see \"Rabies immune globulin (human): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperRAB&reg; S/D: 150 units/mL (2 mL, 10 mL) [solvent/detergent treated]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imogam&reg; Rabies-HT: 150 units/mL (2 mL, 10 mL) [heat treated]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer I.V.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Postexposure wound infiltration: If anatomically feasible, the full rabies immune globulin dose should be infiltrated around and into the wound(s); remaining volume should be administered I.M. in the deltoid muscle of the upper arm or lateral thigh muscle. The gluteal area should be avoided to reduce the risk of sciatic nerve damage. Do not administer rabies vaccine in the same syringe or at the same administration site as RIG.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Measles-containing vaccines should be given &ge;4 months after rabies immune globulin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Part of postexposure prophylaxis of persons with rabies exposure. Provides passive immunity until active immunity with rabies vaccine is established. Not for use in persons with a history of pre-exposure vaccination, history of postexposure prophylaxis, or previous vaccination with rabies vaccine and documentation of antibody response.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever (mild), headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Pain, stiffness, soreness, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotic syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1:1000) should be available. Use with caution in patients with isolated immunoglobulin A deficiency or a history of systemic hypersensitivity to human immunoglobulins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with thrombocytopenia or coagulation disorders; I.M. injections may be contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Not for intravenous administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6801328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Pregnancy is not a contraindication to postexposure prophylaxis.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (HyperRAB S/D Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 units/mL (2 mL): $595.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Imogam Rabies-HT Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 units/mL (2 mL): $492.37",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bayer Bayrab Rabies Immune Globulin (PH);",
"     </li>",
"     <li>",
"      Bayrab (PK);",
"     </li>",
"     <li>",
"      Hyperrab S D (IL);",
"     </li>",
"     <li>",
"      Imogam (AU);",
"     </li>",
"     <li>",
"      Imogam Rabia (AR, PY);",
"     </li>",
"     <li>",
"      Imogam Rabies (BF, BG, BJ, CI, EE, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      PARS (IN);",
"     </li>",
"     <li>",
"      Rabigam (ZA);",
"     </li>",
"     <li>",
"      Rabuman Berna (PH, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rabies immune globulin is a solution of globulins dried from the plasma or serum of selected adult human donors who have been immunized with rabies vaccine and have developed high titers of rabies antibody. It generally contains 10% to 18% of protein of which not less than 80% is monomeric immunoglobulin G.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A New Rabies Vaccine,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1029):64-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6500/abstract-text/9653425/pubmed\" id=\"9653425\" target=\"_blank\">",
"        9653425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2002, 51(RR-2):1-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Human Rabies Prevention - United States, 2008 Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-3):1-28.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-2):1-9. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5902.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5902.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6500/abstract-text/20300058/pubmed\" id=\"20300058\" target=\"_blank\">",
"        20300058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6500/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dreesen DW and Hanlon CA, &ldquo;Current Recommendations for the Prophylaxis and Treatment of Rabies,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(5):801-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6500/abstract-text/9829154/pubmed\" id=\"9829154\" target=\"_blank\">",
"        9829154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang J and Plotkin SA, &ldquo;Rabies Risk and Immunoprophylaxis in Children,&rdquo;",
"      <i>",
"       Adv Pediatr Infect Dis",
"      </i>",
"      , 1997, 13:219-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6500/abstract-text/9544314/pubmed\" id=\"9544314\" target=\"_blank\">",
"        9544314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strady A, Lang J, Lienard M, et al, &ldquo;Antibody Persistence Following Pre-exposure Regimens of Cell-Culture Rabies Vaccines: 10-Year Follow-up and Proposal for a New Booster Policy,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1998, 177(5):1290-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6500/abstract-text/9593014/pubmed\" id=\"9593014\" target=\"_blank\">",
"        9593014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9848 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-1E93B43961-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6500=[""].join("\n");
var outline_f6_22_6500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216777\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216787\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216779\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216783\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216780\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216767\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216755\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216770\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216768\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216785\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216772\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216759\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299975\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216763\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216765\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6801328\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323774\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216774\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216758\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9848\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9848|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/3/20531?source=related_link\">",
"      Rabies immune globulin (human): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/29/41427?source=related_link\">",
"      Rabies immune globulin (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_22_6501="Teriparatide (recombinant human parathyroid hormone (1-34)): Drug information";
var content_f6_22_6501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Teriparatide (recombinant human parathyroid hormone (1-34)): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/5/44116?source=see_link\">",
"    see \"Teriparatide (recombinant human parathyroid hormone (1-34)): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Forteo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Forteo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Parathyroid Hormone Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Osteoporosis:",
"     </b>",
"     SubQ: 20 mcg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Initial administration should occur under circumstances in which the patient may sit or lie down, in the event of orthostasis.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F225840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required. Bioavailability and half-life increase with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute. Use in severe renal impairment is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Forteo&reg;: 250 mcg/mL (2.4 mL) [delivers teriparatide 20 mcg/dose]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F12807316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Forteo&reg;: 250 mcg/mL (3 mL) [delivers teriparatide 20 mcg/dose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088604.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088604.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F225818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by subcutaneous injection into the thigh or abdominal wall. Initial administration should occur under circumstances in which the patient may sit or lie down, in the event of orthostasis.",
"     <b>",
"      Note:",
"     </b>",
"     The 3 mL prefilled pen (Canadian availability; not available in U.S.) must be primed prior to each dose.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of osteoporosis in postmenopausal women at high risk of fracture; treatment of primary or hypogonadal osteoporosis in men at high risk of fracture; treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15255018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Forteo&reg; may be confused with Forfivo&trade; XL",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Endocrine &amp; metabolic: Hypercalcemia (transient increases noted 4-6 hours postdose [women 11%; men 6%])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (5%; transient), chest pain (3%), syncope (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%), insomnia (4% to 5%), anxiety (&le;4%), depression (4%), vertigo (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9% to 14%), gastritis (&le;7%), dyspepsia (5%), vomiting (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (10%), weakness (9%), leg cramps (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (10%), pharyngitis (6%), dyspnea (4% to 6%), pneumonia (4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibodies to teriparatide (3% of women in long-term treatment; hypersensitivity reactions or decreased efficacy were not associated in preclinical trials), herpes zoster (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute dyspnea, allergic reactions, edema (facial/oral), hypercalcemia &gt;13 mg/dL, injection site reactions (bruising, pain, swelling), muscle spasm, osteosarcoma, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to teriparatide or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Pre-existing hypercalcemia; severe renal impairment; metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and Paget&rsquo;s disease of the bone); unexplained elevations of alkaline phosphatase; prior external beam or implant radiation therapy involving the skeleton; bone metastases or history of skeletal malignancies; pregnancy; breast-feeding mothers; pediatric patients or young adults with open epiphysis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Transient orthostatic hypotension usually occurs within 4 hours of dosing and within the first several doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteosarcoma:",
"     <b>",
"      [U.S. Boxed Warning]: In animal studies, teriparatide has been associated with an increase in osteosarcoma;",
"     </b>",
"     risk was dependent on both dose and duration. Avoid use in patients with an increased risk of osteosarcoma (including Paget's disease, prior radiation, unexplained elevation of alkaline phosphatase, or in patients with open epiphyses). Do not use in patients with a history of skeletal metastases, hyperparathyroidism, or pre-existing hypercalcemia.  Exclude metabolic bone disease other than osteoporosis prior to initiating therapy. Not for use in patients with metabolic bone disease other than osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; limited data available concerning safety and efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; limited data available concerning safety and efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; limited data available concerning safety and efficacy. Use in severe renal impairment is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urolithiasis: Use with caution in patients with active or recent urolithiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use of teriparatide for longer than 2 years is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Excessive intake may increase risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Ensure adequate calcium and vitamin D intake.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies; the effect on human fetal development has not been studied. Teriparatide is not indicated for use in pregnant or premenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F225826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indicated for use in postmenopausal women. Studies have not been conducted to determine excretion in breast milk. Not recommended for use in breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Forteo Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mcg/2.4 mL (2.4 mL): $1431.48",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium, serum phosphorus, uric acid; blood pressure; bone mineral density",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Forsteo (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, KP, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Forteo (AR, AU, BR, CN, CO, CR, DO, GT, HK, HN, MX, MY, PA, PE, PH, SV, TH, VE);",
"     </li>",
"     <li>",
"      Human PTH (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teriparatide is a recombinant formulation of endogenous parathyroid hormone (PTH), containing a 34-amino-acid sequence which is identical to the N-terminal portion of this hormone. The pharmacologic activity of teriparatide, which is similar to the physiologic activity of PTH,  includes stimulating osteoblast function, increasing gastrointestinal calcium absorption, and increasing renal tubular reabsorption of calcium. Treatment with teriparatide results in increased bone mineral density, bone mass, and strength. In postmenopausal women, teriparatide has been shown to decrease osteoporosis-related fractures.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (nonspecific proteolysis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 5 minutes; SubQ: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Body JJ, Gaich GA, Scheele WH, et al, &ldquo;A Randomized Double-blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] With Alendronate in Postmenopausal Women With Osteoporosis,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2002, 87(10):4528-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6501/abstract-text/12364430/pubmed\" id=\"12364430\" target=\"_blank\">",
"        12364430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neer RM, Arnaud CD, Zanchetta JR, et al, &ldquo;Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(19):1434-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6501/abstract-text/11346808/pubmed\" id=\"11346808\" target=\"_blank\">",
"        11346808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reeve, J, &ldquo;Recombinant Human Parathyroid Hormone,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2002, 324(7335):435-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6501/abstract-text/11859030/pubmed\" id=\"11859030\" target=\"_blank\">",
"        11859030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saag KG, Shane E, Boonen S, et al, &ldquo;Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(20):2028-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/22/6501/abstract-text/18003959/pubmed\" id=\"18003959\" target=\"_blank\">",
"        18003959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10178 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6501=[""].join("\n");
var outline_f6_22_6501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709064\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225837\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855044\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225853\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225839\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062230\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225840\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225815\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807316\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225800\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874998\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225818\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225817\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255018\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225851\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225821\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225804\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300117\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223234\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225834\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225810\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225825\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225843\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225826\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225824\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225812\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225827\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225803\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225820\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10178\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10178|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/5/44116?source=related_link\">",
"      Teriparatide (recombinant human parathyroid hormone (1-34)): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_22_6502="Bees, yellow jackets, hornets, and wasps: Avoidance";
var content_f6_22_6502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bees, yellow jackets, hornets, and wasps: Avoidance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6502/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6502/contributors\">",
"     Nancy L Breisch, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6502/contributors\">",
"     Albert Greene, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6502/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6502/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6502/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6502/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/22/6502/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stinging Hymenoptera are taxonomically divided into three principal groups: ants, bees, and wasps (",
"    <a class=\"graphic graphic_algorithm graphicRef80397 \" href=\"UTD.htm?24/14/24815\">",
"     algorithm 1",
"    </a>",
"    ). The majority of allergic reactions to stings are due to this order of insects. This topic reviews avoidance of the flying Hymenoptera that include bees, yellow jackets, hornets, and wasps.",
"   </p>",
"   <p>",
"    The biology and identification of the flying Hymenoptera, as well as fire ants, which are also members of the Hymenoptera order, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9271?source=see_link\">",
"     \"Bees, yellow jackets, hornets, and wasps: Biology and identification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7752?source=see_link\">",
"     \"Entomology and control of imported fire ants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis and management of stinging insect allergy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link\">",
"     \"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=see_link\">",
"     \"Diagnosis of Hymenoptera venom allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=see_link\">",
"     \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AVOIDANCE OF STINGS FROM INDIVIDUAL WORKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The public often mistakenly thinks of bees and wasps as inherently aggressive under any circumstances, due to the ease with which some colonies are stimulated to attack in defense of their nest. In reality, individual workers away from the nest tend to narrowly focus on foraging and typically ignore humans, even when close to them. Stings are almost always provoked by firm, accidental contact, such as stepping on a worker, taking the insect into the mouth with food or drink, or",
"    <span class=\"nowrap\">",
"     pressing/striking",
"    </span>",
"    a bee or wasp with the hand. The risk of being stung is therefore elevated in locations where large numbers of bees or wasps have congregated to feed, particularly where humans are doing the same [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Personal behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures in locations such as picnic areas and concession stands involve minimizing accidental contact with foragers. This includes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintaining a high level of vigilance as to the presence of bees and wasps in the immediate vicinity",
"     </li>",
"     <li>",
"      Not walking with exposed feet",
"     </li>",
"     <li>",
"      Exercising care with beverages",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drinking directly out of cans or bottles presents the greatest risk, since these containers are readily entered by inquisitive foragers that are subsequently concealed from view. Tightly lidded cups with inserted straws are often recommended as safer than open cups, but do not totally exclude entry by the smaller species. Open cups or glasses that afford an unobstructed view of the liquid are probably the safest option.",
"   </p>",
"   <p>",
"    There are currently no effective repellent products for foraging bees or wasps, despite advertising claims to the contrary. The most appropriate advice may be to simply not eat or drink outdoors during the warm months, depending upon the extent of a patient's concern [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Wardrobe and cosmetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Public information distributed by the medical community often contains advice concerning wardrobe and cosmetic selection to minimize the chances of being stung, for example: \"Many stinging insects are foraging for food, so don't look or smell like a flower - avoid brightly colored clothing and perfume when outdoors\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/7\">",
"     7",
"    </a>",
"    ]. In fact, there is no empiric evidence that perfume or bright, floral-colored clothing significantly increases a person's attractiveness to foraging Hymenoptera or the risk of getting stung by them.",
"   </p>",
"   <p>",
"    Orientation to flowers by honey bees is governed by a complex suite of integrated factors that include floral colors, patterns, and shapes; specific floral odors supplemented by multiple olfactory cues provided by the local environment; and the recent foraging history of individual workers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. A preconception of what a target item looks like and where it is found, termed the \"search image\", is derived from the aggregate of specific visual stimuli used by an organism to detect its food. Unlike humans, bees are most sensitive to the short-wavelength end of the spectrum, particularly ultraviolet light, followed by blue-violet and green. They are least sensitive to orange and cannot perceive red [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As a result, flowers that depend upon bees for pollination typically have evolved distinctive ultraviolet patterns that are highly visible to the insects, but are often not perceived by humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The search image of foraging bees is therefore unlikely to be triggered by a large patch of colored cloth that appears bright to humans, but has limited or no biologic significance to Hymenoptera [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to apparel, it would seem more likely that some cosmetic fragrances might attract the attention of nearby foragers. Both honey bees and certain vespine species collect carbohydrates from a wide array of natural and manmade sources besides floral nectar, particularly fermenting fruit and sweet beverages and foods [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Orientation to these resources involves olfactory recognition of distinctive volatile cues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Nevertheless, there are no published data demonstrating a significant attractive effect of any cosmetic product for any Hymenoptera species.",
"   </p>",
"   <p>",
"    An example of a different type of potential association between fragrances and stinging risk is the alarm pheromone produced by the giant hornet of Japan, Vespa mandarinia. Alarm pheromones are chemical compounds that are released by bees or wasps to attract other colony members to the location to aid in defense. The giant hornet of Japan has an alarm pheromone that incorporates alcohols and esters that are also used in food flavorings and cosmetic fragrances [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/16\">",
"     16",
"    </a>",
"    ]. However, it is unknown whether or not any specific product incorporating these chemicals elicits defensive behavior by this species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Forager reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to avoiding stings associated with foraging bees and wasps involves implementing measures to reduce the number of foragers.",
"   </p>",
"   <p>",
"    One method is to minimize local sources of attraction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tightly cover food and waste receptacles",
"     </li>",
"     <li>",
"      Frequently clean surfaces of food residue",
"     </li>",
"     <li>",
"      Frequently remove refuse, fallen fruit, and dog or other animal feces (since the attendant flies are hunted by some wasp species)",
"     </li>",
"     <li>",
"      Eliminate landscape plantings that attract large numbers of carbohydrate-seeking Hymenoptera. This measure is generally justified only in extreme circumstances. In many cases, Hymenoptera are not attracted to the flowers or fruit on these plants, but to \"honeydew\", the sugar-rich excrement of sap-sucking insects such as aphids, mealybugs, and scales.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more direct tactic is to attempt to reduce forager populations with the use of baits, either by luring the insects into traps or as a means to deliver a pesticide:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numerous models of wasp traps are on the market [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. However, they tend to be swamped by the constantly replenishing colonies within foraging range unless very large numbers of traps are deployed and continually serviced. Thus, traps are of dubious value in protecting a given location [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toxic baiting programs hold the greatest promise for success, but most aspects of their methodology are still under development [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/15,21-23\">",
"       15,21-23",
"      </a>",
"      ]. Challenges that need to be solved to make this a viable approach include affordability, insecticide efficacy, exclusion of non-target species, and sustainability of bait attractiveness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AVOIDANCE OF STINGS FROM COLONIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practical risk avoidance measures are limited. Maintaining a continuous, effective level of vigilance for social wasp or bee colonies while outdoors is beyond the capability of many people.",
"   </p>",
"   <p>",
"    Group defensive behavior by a social wasp or bee colony may be elicited by considerably more subtle stimuli than the pressure of direct contact needed to provoke stinging from most individual foragers. Typically an abrupt movement of the nest (often due to vibration of its immediate surroundings) will trigger defensive behavior by a colony. However, in some cases, just nearby motion, the approach of a dark object, or mammalian breath, is a sufficient stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/1,24-26\">",
"     1,24-26",
"    </a>",
"    ]. The consequences for the human or animal source of the disturbance are usually far more severe than from an encounter with an individual forager. Many species use an alarm pheromone to rapidly recruit workers for defense during an emergency. Thus, large colonies are potentially capable of delivering hundreds, or even thousands, of stings almost instantaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/25,27\">",
"     25,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arousal thresholds and intensity of aggressive response vary widely among social Hymenoptera, and are dependent upon genetic lineage and a colony's age, size, and history of disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/1,24,26,28\">",
"     1,24,26,28",
"    </a>",
"    ]. A colony that was previously aroused will often attack with far less provocation than one that has never been disturbed. The major problem universally posed by these insects is the cryptic nature of their nests, many of which are totally concealed in protected cavities either above or below ground. Even large, exposed nests in vegetation or attached to structures are typically obscured by foliage, overhangs, or shadow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Colony control and avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visible nests should be removed by a trained professional. In addition, individuals with stinging insect allergy should avoid activities that may disturb a colony, such as mowing the lawn or pruning a hedge.",
"   </p>",
"   <p>",
"    Preventive measures normally involve killing the workers (or sometimes capturing them, in the case of honey bees) if a social wasp or bee nest is observed in an undesirable location. This activity should not be attempted by anyone other than a licensed pest control professional who has received specialized training and is equipped with clothing designed specifically to protect against stings, even though insecticide products labeled for stinging insect control are readily available to the general public [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The process often requires extensive measures to protect the safety of bystanders [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The precise methodology of nest control operations is highly variable, depending upon species and circumstances, and is beyond the scope of this topic review.",
"   </p>",
"   <p>",
"    An undiscovered, concealed bee or wasp nest is the most hazardous and may be encountered virtually anywhere. The single greatest risk factor for multiple stinging by a disturbed colony is simply being outdoors in a spot not frequented by humans. This typically implies an area with vegetation. Thus, the more time spent in natural locales (particularly off well-established paths), the higher the risk. For people who live and work in developed locations, activities in parks, yards, or gardens are most likely to bring them into accidental contact with a social bee or wasp nest. Those activities producing vibration and disturbance to vegetation, such as accompanying a dog or mowing, pruning, or string-trimming are most likely to result in stinging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. In particular, gasoline-powered lawn mowers have the distinction of being perhaps the most efficient means for stimulating wasp or bee colonies to attack. These machines are \"the perfect predator\" from the insects' point of view, since they produce noise, vibration, odors, and heat [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Personal rescue actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outdoor activities are either difficult to avoid or highly pleasurable for many people, therefore the most useful advice often involves a few common-sense guidelines for personal behavior once a nest is disturbed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/25,31\">",
"     25,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals should slowly walk away from the area without flailing the arms if only a few bees or wasps are flying around them. Sudden motion often exacerbates attack behavior and increases the chance of accidental contact.",
"     </li>",
"     <li>",
"      Individuals should cover their mouth and nose and run from the area without delay if many insects suddenly start to fly around them or if they are being stung. Stinging insects tend to target the facial area, which can quickly produce panic and disorientation in the victim.",
"     </li>",
"     <li>",
"      If possible, persons under attack by bees or wasps should seek shelter in a building or enclosed vehicle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mitigating the severity of attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few readily-deployed measures that might mitigate the intensity of social insect defensive reactions are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacking bees and wasps are strongly attracted to dark colors (one reason why eyes, mouth, and nostrils are selectively targeted), so white or very light-colored clothing that covers most of the body should confer some advantage [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mixed results have been reported on the efficacy of an aerosol spray of the common insect repellent N,N-diethyl-m-toluamide (DEET) in decreasing the magnitude of mass honey bee attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smoke reduces defensive behavior in both honey bees and yellow jackets [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/32\">",
"       32",
"      </a>",
"      ], although this would seem to have limited practical value in an unexpected confrontation.",
"     </li>",
"     <li>",
"      Persons with outdoor occupations that present an elevated risk for disturbing bee and wasp colonies have the option of carrying at least minimal protective equipment with them (eg, a compact mesh veil to cover the head). Firefighters in natural areas are urged to take refuge in a personal fire shelter (a standard protective item made from aluminum foil, fiberglass, and woven silica) in the case of severe stinging insect attack [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6502/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contrary to popular folklore, worker bees and wasps away from their nests are not aggressive toward humans and have to be firmly touched before they will sting. Personal protection therefore largely involves heightened awareness in areas where these insects are abundant, particularly when eating or drinking. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Avoidance of stings from individual workers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Personal behavior'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is currently no evidence that wearing perfume or bright, floral-colored clothing attracts bees and wasps, or elevates sting risk, despite widespread advice to the contrary. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Wardrobe and cosmetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sanitation measures that minimize food and food waste available to worker bees and wasps tend to be more effective in reducing their numbers than other methods. Toxic baiting techniques for area-wide abatement of foraging yellow jackets are still largely in the experimental stage. Available traps for these wasps typically do not capture sufficient workers to significantly reduce sting risk. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Forager reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventing stings from colonies is more problematic than with individual foragers, and depends mostly upon personal awareness when disturbing vegetation, particularly when doing yard work. The most effective measure in mitigating the severity of a mass attack is probably the wearing of white or light-colored clothing while outdoors. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Avoidance of stings from colonies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals should back slowly away from the area without making any sudden movements if a few bees or wasps start flying around them. However, individuals should cover their mouth and nose and run from the area and seek shelter in a building or enclosed vehicle if large numbers of insects begin flying around them or they are being stung. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Personal rescue actions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Akre RD, MacDonald JF. Biology, economic importance and control of yellow jackets. In: Economic impact and control of social insects, Vinson SB (Ed), Praeger, New York 1986. p.353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/2\">",
"      Vetter RS, Visscher PK. Bites and stings of medically important venomous arthropods. Int J Dermatol 1998; 37:481.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett GW, Owens JM, Corrigan RM. Truman's scientific guide to pest management operations, Advanstar, Cleveland 2003.",
"    </li>",
"    <li>",
"     Mallis A. Handbook of pest control, GIE Media, Cleveland 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/5\">",
"      Pinto L. Using IPM against yellowjackets and honey bees. Pest Control 1988; 66:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/6\">",
"      Greene A, Breisch NL. Avoidance of bee and wasp stings: an entomological perspective. Curr Opin Allergy Clin Immunol 2005; 5:337.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Allergy, Asthma, and Immunology, Public Education Committee. Tips to remember: Stinging insect allergy. www.aaaai.org/patients/publicedmat/tips/stinginginsect.stm (Accessed on July 15, 2009).",
"    </li>",
"    <li>",
"     Michener CD. The bees of the world, Johns Hopkins Univ Press, Baltimore 2007.",
"    </li>",
"    <li>",
"     Winston ML. The biology of the honey bee, Harvard Univ Press, Cambridge, MA 1987.",
"    </li>",
"    <li>",
"     Gould JL, Gould CG. The honey bee, Scientific Amer Library, New York 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/11\">",
"      Free JB. The effect of flower shape and nectar guides on the behaviour of foraging honeybees. Behaviour 1970; 37:269.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards R. Social wasps: Their biology and control, Rentokil, East Grinstead, UK 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/13\">",
"      Richter MR. Social wasp (Hymenoptera: Vespidae) foraging behavior. Annu Rev Entomol 2000; 45:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/14\">",
"      Jander R. Olfactory learning of fruit odors in the eastern yellow jacket, Vespula maculifrons (Hymenoptera: Vespidae). J Insect Behav 1998; 11:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/15\">",
"      Day SE, Jeanne RL. Food volatiles as attractants for yellowjackets (Hymenoptera: Vespidae). Environ Entomol 2001; 30:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/16\">",
"      Ono M, Terabe H, Hori H, Sasaki M. Insect signalling: components of giant hornet alarm pheromone. Nature 2003; 424:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/17\">",
"      Christie GD. Evaluation of non-toxic bait traps for yellowjacket control. Pest Control 1994; 62:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/18\">",
"      Gulmahamad H. Yellowjacket control gets creative. Pest Control 2002; 70:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/19\">",
"      Cooper P. Taking the bite out of bee sting occurrences. Pest Control 1998; 66:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/20\">",
"      Toft RJ, Harris RJ. Can trapping control Asian paper wasp (Polistes chinensis antennalis) populations. N Z J Ecol 2004; 28:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/21\">",
"      Beggs JR, Toft RJ, Malham JP, et al. The difficulty of reducing introduced wasp (Vespula vulgaris) populations for conservation gains. N Z J Ecol 1998; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/22\">",
"      Harris RJ, Etheridge ND. Comparison of baits containing fipronil and sulfluramid for the control of Vespula wasps. N Z J Zool 2001; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/23\">",
"      Sackmann P, Rabinovich M, Corley JC. Successful removal of German yellowjackets (Hymenoptera: Vespidae) by toxic baiting. J Econ Entomol 2001; 94:811.",
"     </a>",
"    </li>",
"    <li>",
"     Akre RD, Reed HC. Vespine defense. In: Defensive mechanisms in social insects, Hermann HR (Ed), Praeger, New York 1984. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/25\">",
"      Schmidt JO, Boyer Hassen LV. When Africanized bees attack: what you and your clients should know. Vet Med 1996; 91:923.",
"     </a>",
"    </li>",
"    <li>",
"     Schmidt JO. Mass action in honey bees: Alarm, swarming and the role of releaser pheromones. In: Pheromone communication in social insects, Meer RK, Breed MD, Espelie KE, Winston ML (Eds), Westview Press, Boulder, CO 1988. p.257.",
"    </li>",
"    <li>",
"     Winston ML. Killer bees: The Africanized honey bee in the Americas., Harvard Univ Press, Cambridge, MA 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/28\">",
"      Breed MD, Guzm&aacute;n-Novoa E, Hunt GJ. Defensive behavior of honey bees: organization, genetics, and comparisons with other bees. Annu Rev Entomol 2004; 49:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/29\">",
"      Greene A. Born to gnaw. Pest Control Tech 2003; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/30\">",
"      Greene A. Sucking up stingers. Pest Control Tech 2004; 32:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/31\">",
"      Vetter RS, Parker BT, Visscher PK. Can fire shelters protect firefighters from bee and yellowjacket stings. Fire Mgmt Notes 1998; 58:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/32\">",
"      Visscher PK, Vetter RS. Smoke and target color effects on defensive behavior in yellowjacket wasps and bumble bees (Hymenoptera: Vespidae, Apidae) with a description of an electronic attack monitor. J Econ Entomol 1995; 88:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/33\">",
"      Collins AM, Rubink WL, Cuadriello Aguilar JI, Hellmich RL II. Use of insect repellents for dispersing defending honey bees (Hymenoptera: Apidae). J Econ Entomol 1996; 89:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6502/abstract/34\">",
"      Schmidt JO, Johnston AN, Ginter DL, Spangler HG. Olfactory stimulation of Africanized honey bee (Hymenoptera: Apidae) attacks by insect repellents. J Med Entomol 2003; 40:275.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4094 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6502=[""].join("\n");
var outline_f6_22_6502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AVOIDANCE OF STINGS FROM INDIVIDUAL WORKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Personal behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Wardrobe and cosmetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Forager reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AVOIDANCE OF STINGS FROM COLONIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Colony control and avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Personal rescue actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mitigating the severity of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4094|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/14/24815\" title=\"algorithm 1\">",
"      Hymenoptera taxonomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=related_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9271?source=related_link\">",
"      Bees, yellow jackets, hornets, and wasps: Biology and identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=related_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7752?source=related_link\">",
"      Entomology and control of imported fire ants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_22_6503="Prognostic molecular profiles of breast cancer";
var content_f6_22_6503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognostic molecular profiles of breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6503/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6503/contributors\">",
"     Lisa A Carey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6503/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6503/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6503/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/22/6503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is a heterogeneous and phenotypically diverse disease. It is composed of several biologic subtypes that have distinct behaviors and responses to therapy. This heterogeneity was first noted over 100 years ago with the identification that simple removal of the ovaries was therapeutic in some breast cancer patients, but not others. Breast cancer characterization (profiling) has significantly advanced since the turn of the millennium due to the development of sophisticated technologies, such as gene expression arrays, which permit simultaneous measurement of thousands of genes to create a molecular portrait of the tumor.",
"   </p>",
"   <p>",
"    The emergence of genomic techniques and the ability to simultaneously measure the expression of thousands of genes have led to the identification of biology-based prognostic profiles, several of which have been validated and are in clinical use. The development of prognostic profiles has been particularly useful in guiding decision-making about adjuvant therapy along with well-established clinical prognostic factors (eg, patient age, comorbidity, tumor size, grade, and nodal status) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These molecular prognostic profiles can augment but do not replace classic clinical factors.",
"   </p>",
"   <p>",
"    Molecular prognostic signatures in breast cancer will be reviewed here. Breast cancer subtypes, which have also been identified through gene expression profiling, other prognostic and predictive markers used for breast cancer, and an overview of gene expression profiling are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41302?source=see_link\">",
"       \"Molecular intrinsic subtypes of breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"       \"Measurement of prognostic factors in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"       \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1237831259\">",
"    <span class=\"h1\">",
"     PROGNOSTIC VERSUS PREDICTIVE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, a",
"    <strong>",
"     prognostic",
"    </strong>",
"    factor is capable of providing information on clinical outcome at the time of diagnosis, independent of therapy. Such markers are usually indicators of growth, invasion, and metastatic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In contrast, a",
"    <strong>",
"     predictive",
"    </strong>",
"    factor is capable of providing information on the likelihood of response to a given therapeutic modality. Such markers are either within the target of the treatment or serve as modulators or epiphenomena related to expression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function of the target. Although they can be separately classified, several factors in breast cancer are both prognostic and predictive, including expression of the estrogen receptor (ER) and the presence of overexpression of the human epidermal growth factor-2 (HER2) receptor. As discussed below, some evidence suggests that molecular profiles can also provide prognostic and predictive information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1237831274\">",
"    <span class=\"h1\">",
"     MOLECULAR PROFILES IN BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three most commonly used molecular prognostic profiles are the Recurrence Score (RS), derived from Oncotype DX, the Amsterdam 70-gene profile (Mammaprint), and the Risk of Recurrence score (derived from PAM50). These are described in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027181923\">",
"    <span class=\"h2\">",
"     Criteria for evaluation of molecular profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;In evaluating any molecular signature, it is important to consider several criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Was the signature created from a dataset that is independent from the validation signature?",
"     </li>",
"     <li>",
"      Was the signature validated in large, multicenter, prospectively annotated datasets?",
"     </li>",
"     <li>",
"      What information does the signature provide, and what population is it",
"      <span class=\"nowrap\">",
"       appropriate/validated",
"      </span>",
"      for?",
"     </li>",
"     <li>",
"      What population or application should it be used in? Where should it not be used?",
"     </li>",
"     <li>",
"      How much does the signature reflect commonly measured prognostic variables (eg, hormone status, stage, or grade) or does it provide truly independent information?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to better detect distant (rather than all) recurrences and early (rather than late) recurrences are limitations of molecular profiles in use clinically, because these estimates are a function of the dataset from which they are derived and the methodology used to derive them. Because molecular profiles have been derived from younger patients in general (ie, age &lt;65), a profile for distant metastases within a five-year time frame in young patients is likely to predict exactly that. It is likely to be less predictive in older patients. Therefore, caution is needed when extrapolating to patient populations other than those studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recurrence score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 21-gene recurrence score (RS, Oncotype Dx) is among the best-validated prognostic assays. It also appears to predict response to systemic chemotherapy. It is the most widely used in women with node-negative, estrogen receptor (ER)-positive breast cancer, which is consistent with guidelines put forth by the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182678\">",
"    <span class=\"h3\">",
"     Development of the RS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RS was developed by identifying the 250 most promising candidate genes described in the literature. Investigators then used a reverse transcription polymerase chain reaction (RT-PCR)-based method for generating quantitative expression levels of these genes in fixed tissue from 447 patients collected from three datasets. A mathematical formula that includes 16 genes (plus five reference genes) was then generated to optimize prediction of distant relapse despite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy. The sum of this calculation is known as the RS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182685\">",
"    <span class=\"h3\">",
"     Validation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RS was validated in an independent dataset derived from 668 samples collected in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    -treated arm of National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 trial, a prospective randomized clinical trial examining the benefit of adjuvant tamoxifen in hormone receptor-positive, node-negative breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/6\">",
"     6",
"    </a>",
"    ]. Although this population had a generally good prognosis, the rate of distant recurrence at 10 years was 7, 14, and 31 percent for patients with a low (RS &lt;18), intermediate (RS 18 to 30), or high score (RS &gt;30) respectively.",
"   </p>",
"   <p>",
"    Further analysis showed that for women on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , the RS was also predictive of locoregional and distant recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/7\">",
"     7",
"    </a>",
"    ]. Similar findings have been reported with aromatase inhibitors in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/8\">",
"     8",
"    </a>",
"    ], suggesting that the RS identifies relative endocrine insensitivity as a general phenomenon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182725\">",
"    <span class=\"h3\">",
"     Predicting benefit from chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies suggest that a high RS predicts patients who will benefit from chemotherapy in the context of either pathologically negative [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] or positive node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/8,10,12\">",
"     8,10,12",
"    </a>",
"    ]. This is illustrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of patients with pathologically node-negative breast cancer treated in NSABP B-20, the addition of CMF (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ) to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      resulted in a higher rate of distant disease free survival at 10 years among patients with a high RS compared to treatment with tamoxifen alone (88 versus 60 percent, respectively; relative risk [RR] 0.26, 95% CI 0.13-0.53) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/9\">",
"       9",
"      </a>",
"      ]. However, there was little evidence of a benefit with the addition of CMF among those with a low RS (96 versus 97 percent; RR 1.31, 95% CI 0.46-3.78) or an intermediate RS (90 versus 91 percent; RR 0.61, 95% CI 0.24-1.59).",
"      <br/>",
"      <br/>",
"      Although it has been argued that the value of the RS can be estimated with improvements in pathologic grading and quantitative hormone receptor scoring, this study suggests that may not be true. Even with central laboratory grading, 19 percent of high-grade tumors had a low RS and 5 percent of low-grade tumors had a high RS.",
"     </li>",
"     <li>",
"      A separate study examined a subset of 367 tumors from postmenopausal women with pathologically node-positive, hormone receptor-positive breast cancer treated on Southwest Oncology Group (SWOG)-8814 who had been randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      alone or six cycles of CAF (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ) chemotherapy followed by tamoxifen [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/10\">",
"       10",
"      </a>",
"      ]. Compared to tamoxifen alone, the addition of CAF among women with a high RS resulted in improvements in 10-year disease-free survival (55 versus 43 percent, respectively; hazard rate [HR] 0.59, 95% CI 0.35-1.01) and overall survival (73 versus 54 percent, respectively; HR 0.56, 95% CI 0.31-1.02). These results were not seen among women with a low or intermediate RS. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combined prognostic and predictive ability of RS, albeit limited, is the reason that the RS is incorporated into adjuvant decision-making for node-negative disease, as suggested by the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for breast cancer, and the St Gallen International Expert Consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. While it appears that the RS is helpful to determine those patients least likely to benefit from the addition of chemotherapy, two issues remain unresolved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To date, it is not clear at which RS cut-off chemotherapy should or should not be administered. The recently completed",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00310180\">",
"       TAILORx trial",
"      </a>",
"      will hopefully provide better data to inform the role of the RS in identifying those node-negative patients who may and those who may not benefit from chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/15\">",
"       15",
"      </a>",
"      ]. In this trial, women with an RS between 11 and 25 were randomly assigned treatment with either endocrine therapy versus chemotherapy followed by endocrine therapy.",
"     </li>",
"     <li>",
"      Although the data from the SWOG study discussed above suggests a role for the RS in patients with pathologically involved lymph nodes, we await the results from prospective studies to better inform this application of the RS. The",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT01272037\">",
"       Southwest Oncology Group S1007 RxPONDER trial",
"      </a>",
"      , which utilizes the RS to assign hormone receptor-positive, HER2-negative, node-positive patients to standard endocrine therapy with or without adjuvant chemotherapy, is ongoing [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amsterdam 70-gene profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Amsterdam 70-gene prognostic profile (Mammaprint) was one of the first gene expression array-based marketed for prognostic purposes. Although it was originally approved for use with unfixed, frozen tissue, it has now been adapted for use with formalin-fixed, paraffin-embedded tissue. Unlike Oncotype DX, it can be used to determine the prognosis in patients with breast cancer regardless of hormone receptor-status and in patients with human epidermal growth factor 2 (HER2) positive disease. However, it does not provide predictive information on the utility of adjuvant therapy in patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182740\">",
"    <span class=\"h3\">",
"     Development of the 70-gene profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 70-gene-profile was developed using a supervised DNA microarray analysis of gene expression arrays on frozen tissue from 98 primary breast tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/17\">",
"     17",
"    </a>",
"    ]. A mathematical model is used to calculate a score that stratifies patients as having a breast cancer with an associated poor-prognosis or good-prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182747\">",
"    <span class=\"h3\">",
"     Validation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 70-gene prognostic profile has been validated in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study involved patients (age &lt;53 at diagnosis) with T1 to T2 node-negative (n = 151) or node-positive (n = 144) breast cancer followed for nearly seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/18\">",
"       18",
"      </a>",
"      ]. The 10 year survival rates were 55 and 95 percent with the poor- and good-prognosis gene signatures, respectively. The poor-prognosis signature was significantly associated with an increased risk of distant metastases at 10 years (49 versus 15 percent, hazard ratio [HR] 5.1, 95% CI 2.9 to 9.0).",
"     </li>",
"     <li>",
"      A subsequent study was performed using data from 302 women under age 60 with node-negative T1 to T2 tumors. Patients were treated without adjuvant systemic chemotherapy and were followed for over 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/19\">",
"       19",
"      </a>",
"      ]. The 70-gene signature did better in predicting outcomes than clinical factors (assessed using Adjuvant! Online), including time to distant metastasis (HR 2.13) and overall survival (HR 2.63), but not disease-free survival (HR 1.36). The 10 year overall survival rate was 70 versus 90 percent among women in the poor- or good-prognosis signature group, respectively.",
"     </li>",
"     <li>",
"      A separate study evaluated the role of the 70-gene signature in women with a T1 breast cancer (size &le;2 cm) and reported that a poor-prognosis signature was associated with lower breast cancer specific survival at 10 years compared to those with a good-prognosis signature (72 versus 91 percent, respectively; HR for mortality, 3.25, 95% CI 1.92-5.51) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/21\">",
"       21",
"      </a>",
"      ]. The identification of a low risk group by prognosis signature was independent of nodal status, tumor grade, ER and HER2 status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical utility of the 70-gene profile will come from a large international study, the",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00433589\">",
"     Microarray in Node-Negative Disease May Avoid Chemotherapy (MINDACT) trial",
"    </a>",
"    , in which women with node negative breast cancer undergo clinical risk assessment (using Adjuvant! Online and the 70-gene signature) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with discordant clinical and genomic predictions are randomly assigned to receive or not receive adjuvant chemotherapy. This trial has completed accrual, and we await results to be presented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182187\">",
"    <span class=\"h2\">",
"     PAM50 Risk of Recurrence Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Predictor Analysis of Microarray 50 (PAM50) is a 50-gene test that characterizes an individual tumor by intrinsic subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/23\">",
"     23",
"    </a>",
"    ]. Results from the PAM50 are used to generate the risk of recurrence (ROR) score, which can stratify patients with estrogen receptor-positive disease into high, medium, and low subsets. The test can be performed on formalin-fixed paraffin-embedded tissue. While not available for use in the US, it is available in the European Union.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182762\">",
"    <span class=\"h3\">",
"     Development of the ROR score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PAM50 was developed using microarray and quantitative RT-PCR data from a set of almost 190 prototype samples [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/23\">",
"     23",
"    </a>",
"    ]. In the initial testing set that included over 700 samples, a continuous score was developed comprised of the intrinsic subtype (defined by the PAM50) and tumor size, called the ROR score. The ROR was significantly predictive of prognosis among patients with node-negative breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027182769\">",
"    <span class=\"h3\">",
"     Validation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PAM50 and ROR score has been subsequently validated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Using data from two separate trials, the ROR score and PAM50 added prognostic information beyond what could be assessed by clinical factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In one study, the ROR outperformed the RS in its ability to stratify patients with hormone receptor-positive, node-negative breast cancer into the high rather than intermediate risk group [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/26\">",
"     26",
"    </a>",
"    ], suggesting the ROR may be a better prognostic indicator than the RS among this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1644710771\">",
"    <span class=\"h2\">",
"     Other genomic signatures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     76-gene signature",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     Rotterdam/Veridex",
"    </span>",
"    76-gene prognostic signature was developed in a test set of 115 node-negative primary breast cancers from women who did not receive adjuvant therapy and had been followed for more than eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/28\">",
"     28",
"    </a>",
"    ]. Recognizing the genetic heterogeneity of breast cancer, separate prognostic gene sets were developed for ER-negative (comprised of 16 genes) and ER-positive (comprised of 60 genes) disease.",
"   </p>",
"   <p>",
"    The 76 prognostic gene signature was validated in an independent set of 171 tumors, demonstrating 93 percent sensitivity and 48 percent specificity. It also predicted distant metastasis-free survival independent of clinical variables. Subsequent studies have validates the prognostic ability of this signature for relapse free survival, particularly among patients with ER-positive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Further studies are required to validate this test prior to its use in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1644710909\">",
"    <span class=\"h3\">",
"     Breast cancer index (BCI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BCI is a combination of two profiles, the HOXB13-to-IL17BR expression ratio (H:I ratio) and the Molecular Grade Index (MGI). Using genome-wide microarray analysis, three differentially expressed genes were identified: the antiapoptotic homeobox B13 (HOXB13, overexpressed in women who took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and then recurred) and both interleukin 17B receptor (IL17BR) and EST AI240933 (overexpressed in women who took tamoxifen regardless of whether they recurred or not) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/31\">",
"     31",
"    </a>",
"    ]. Compared to clinical prognostic factors (eg, age, tumor size, tumor grade, and lymph node status), the H:I ratio was significantly and independently correlated with outcome (odds ratio [OR] 7.3, 95% CI 2.1-26).",
"   </p>",
"   <p>",
"    Subsequent studies have validated the BCI as an accurate predictor of endocrine responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/32\">",
"     32",
"    </a>",
"    ] and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6503/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Given the emerging role of extended adjuvant therapy, efforts to identify those patients more likely to benefit is of great potential value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H38114838#H38114838\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Duration of endocrine treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gene expression profiling is the simultaneous analysis of expression of large numbers of genes. It has been used to develop breast cancer molecular signatures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molecular signatures offer the potential for use in clinical practice for prognostic stratification and treatment selection for patients with breast cancer, particularly if they are hormone receptor-positive. These molecular prognostic profiles augment, but do not replace classic clinical factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most validated signatures in breast cancer include the 21-gene recurrence score (RS, Oncotype Dx), the Amsterdam 70-gene profile, and the PAM50 Risk of Recurrence (ROR) score. All of these techniques can be performed on formalin-fixed paraffin-embedded tissue. (See",
"      <a class=\"local\" href=\"#H1237831274\">",
"       'Molecular profiles in breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the ability of these signatures to inform prognosis, none provide insight into the optimal choice of chemotherapy regimen, if indicated. (See",
"      <a class=\"local\" href=\"#H1237831259\">",
"       'Prognostic versus predictive factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We support obtaining the RS in patients with hormone receptor-positive, HER2-negative, pathologically node-negative breast cancer in whom chemotherapy added to endocrine therapy is considered. It is not clear what additional (or alternative) advantages other genomic profiles offer at this time. We await results of ongoing clinical trials to inform the roles of other signatures in the management of newly diagnosed breast cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Recurrence score'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Amsterdam 70-gene profile is a reasonable alternative to the RS for informing the prognosis of patients with newly diagnosed breast cancer. However, there are insufficient data about the clinical utility of this tool in decision-making about chemotherapy benefit for patients with ER-positive disease. It does not provide value in recommendations for systemic treatment for patients with ER-negative disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Amsterdam 70-gene profile'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The PAM50 ROR is a reasonable alternative to the RS to assign patients with hormone receptor-positive disease into different prognostic groups. However, like the Amsterdam 70-gene profile, there are insufficient data regarding the clinical utility of this tool in determining the role of chemotherapy for these patients. (See",
"      <a class=\"local\" href=\"#H1027182187\">",
"       'PAM50 Risk of Recurrence Score'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of other signatures are under development, including the two-gene signature (HOX13:IL17BR), which may prove useful in identifying endocrine sensitivity and late relapse. (See",
"      <a class=\"local\" href=\"#H1644710771\">",
"       'Other genomic signatures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Adjuvant! Online file://www.adjuvantonline.com/index.jsp (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/2\">",
"      Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/3\">",
"      Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/4\">",
"      Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is \"statistically significant\" clinically useful? Breast Cancer Res Treat 1998; 52:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/5\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/6\">",
"      Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/7\">",
"      Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010; 28:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/8\">",
"      Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/9\">",
"      Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/10\">",
"      Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/11\">",
"      Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23:7265.",
"     </a>",
"    </li>",
"    <li>",
"     Goldstein L, Ravdin P, Gray R, et al. Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197. Cancer Research 2007 (abstr 63).",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/14\">",
"      Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319.",
"     </a>",
"    </li>",
"    <li>",
"     Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial) file://www.cancer.gov/clinicaltrials/ECOG-PACCT-1 (Accessed on May 25, 2011).",
"    </li>",
"    <li>",
"     Trial information available online at file://clinicaltrials.gov/ct2/show/NCT01272037?term=S1007+and+breast+cancer&amp;rank=1 (Accessed on June 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/17\">",
"      van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/18\">",
"      van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/19\">",
"      Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/20\">",
"      Mook S, Schmidt MK, Weigelt B, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010; 21:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/21\">",
"      Mook S, Knauer M, Bueno-de-Mesquita JM, et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010; 17:1406.",
"     </a>",
"    </li>",
"    <li>",
"     EORTC Trial 10041 (BIG 3-04) - MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy). A prospective randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0-3 positive nodes.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/23\">",
"      Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/24\">",
"      Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16:5222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/25\">",
"      Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012; 18:4465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/26\">",
"      Dowsett M, Lopez-Knowles E, Sidhu K. Comparison of PAM50 risk of recurrence (ROR) score with oncotypeDx and IHC4 for predicting residual risk of RFS and distant RFS after endocrine therapy: A TransATAC study. Cancer Res 2011; 71:Abstract nr S4/5.",
"     </a>",
"    </li>",
"    <li>",
"     Gnant M, Filipits M, B Mlineritsch B, et al. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study. Cancer Res 2012; 72: Abstract nr S4/3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/28\">",
"      Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/29\">",
"      Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/30\">",
"      Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007; 13:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/31\">",
"      Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6503/abstract/32\">",
"      Jansen MP, Sieuwerts AM, Look MP, et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 2007; 25:662.",
"     </a>",
"    </li>",
"    <li>",
"     Sgroi DC, Sestak I, Cuzick J, et al. Comparative performance of breast cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: A TransATAC Study. Cancer Res 2012; 72 (24 Suppl); Abstract nr S1-9.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 790 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6503=[""].join("\n");
var outline_f6_22_6503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1237831259\">",
"      PROGNOSTIC VERSUS PREDICTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1237831274\">",
"      MOLECULAR PROFILES IN BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1027181923\">",
"      Criteria for evaluation of molecular profiles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recurrence score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182678\">",
"      - Development of the RS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182685\">",
"      - Validation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182725\">",
"      - Predicting benefit from chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amsterdam 70-gene profile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182740\">",
"      - Development of the 70-gene profile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182747\">",
"      - Validation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182187\">",
"      PAM50 Risk of Recurrence Score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182762\">",
"      - Development of the ROR score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1027182769\">",
"      - Validation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1644710771\">",
"      Other genomic signatures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - 76-gene signature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1644710909\">",
"      - Breast cancer index (BCI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41302?source=related_link\">",
"      Molecular intrinsic subtypes of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_22_6504="Lichenoid interface dermatitis";
var content_f6_22_6504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Lichenoid interface dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichenoid interface dermatitis resembling that of idiopathic lichen planus.",
"    <br/>",
"    (A) Compact hyperorthokeratosis, thickened stratum granulosum and irregular acanthosis of the epidermis together with a superficial lichenoid lymphocytic infiltrate (hematoxylin-eosin, x100).",
"    <br/>",
"    (B and C) Higher magnification with necrotic keratinocytes up to the mid-epidermal layers (hematoxylin-eosin, x200).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6504=[""].join("\n");
var outline_f6_22_6504=null;
var title_f6_22_6505="Coronary artery bypass graft surgery after acute ST elevation myocardial infarction";
var content_f6_22_6505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Oz M Shapira, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6505/contributors\">",
"     John A Bittl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/22/6505/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/22/6505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute ST-elevation myocardial infarction (STEMI), prompt restoration of myocardial blood flow is essential to optimize myocardial salvage and decrease mortality. This is particularly important in the first few hours after symptom onset, when the amount of myocardium salvageable by reperfusion is greatest. Coronary artery reperfusion, if performed in a timely manner, improves clinical outcomes compared to no reperfusion in nearly all groups of patients with an acute ST elevation myocardial infarction (STEMI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both primary percutaneous coronary intervention (PCI) and fibrinolysis can restore blood flow in an acutely occluded coronary artery in a much shorter time than can coronary artery bypass graft surgery (CABG) and these procedures are preferred to CABG in most cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will address the indications, optimal timing, technical considerations, and outcomes of urgent or emergent CABG in patients with acute STEMI. The role of CABG in patients with non-ST elevation MI or unstable angina is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all studies of percutaneous coronary intervention (PCI) or fibrinolysis, outcomes improve as the time from symptom onset to reperfusion decreases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, PCI or fibrinolysis can usually restore flow to the ischemic myocardium more quickly than CABG, largely attributable to delays in getting the patient to the operating room and the time it takes to complete the bypass surgical procedure. Thus, CABG is uncommonly used as the reperfusion strategy of choice in STEMI; it is estimated that CABG is performed in 5 percent or less of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CABG may be considered for the following subgroups of patients with STEMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     After unsuccessful or complicated PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most acute STEMI cases, the site of occlusion responsible for the MI can be identified and successfully opened with PCI and stenting. When successful, this leads to an improvement in clinical and electrocardiographic signs of ischemia. In a small minority of cases, either the culprit lesion cannot be identified or reperfusion cannot be reestablished. In such cases, patients with ongoing ischemia may benefit from",
"    <span class=\"nowrap\">",
"     urgent/emergent",
"    </span>",
"    CABG in an effort to minimize myocardial damage and decrease in-hospital morbidity and mortality.",
"   </p>",
"   <p>",
"    Increased interventional experience and advances in technology have led to a decline in the incidence of acute complications of PCI (irrespective of whether it is in the setting of STEMI or not) to the range of 2 to 4 percent. Examples of complications for which urgent CABG might be indicated include failed stent deployment, extensive coronary artery dissection, perforation of a coronary artery leading to pericardial tamponade, or recurrent acute closure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H22#H22\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Emergency CABG for failed PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with either unsuccessful or complicated PCI who have ongoing ischemia and anatomy suitable for CABG should be referred for consideration of CABG as opposed to a strategy of medical therapy only. The rationale includes: older studies demonstrating acceptable surgical mortality after CABG in patients with failed balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]; small observational studies that have shown benefit from CABG after PCI in patients with cardiogenic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/7\">",
"     7",
"    </a>",
"    ]; and evidence from all studies of patients who are reperfused with either fibrinolytic therapy or primary PCI in which outcomes are uniformly better than with medical therapy alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks and benefits should be discussed among members of a multidisciplinary team and with the patient and family. Factors favoring emergent CABG include a large amount of ischemic myocardium, good general health, bypassable vessels, and the ability to perform surgery within six hours of the PCI. The presence of life-threatening ventricular arrhythmia should also drive the decision for emergent CABG. (See",
"    <a class=\"local\" href=\"#H358599859\">",
"     'Life threatening ventricular arrhythmias'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanical complications of acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical complications of acute MI include rupture of the left ventricular free wall or interventricular septum and acute mitral regurgitation. Medical treatment alone results in close to 100 percent mortality in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/8\">",
"     8",
"    </a>",
"    ]. Most of these patients will require emergency cardiac surgical repair of the mechanical defect; CABG will be performed at that time. The approach to these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We prefer immediate CABG, as opposed to PCI of the infarct related artery followed by CABG and repair of the mechanical defect since termination of the ischemia often does not lessen the adverse hemodynamic impact of the mechanical defect, which may cause death. However, in some patients it may be appropriate to initially reperfuse the patient with PCI and then have the patient undergo cardiac surgery. For example, a patient with an acutely occluded (culprit) lesion in the circumflex coronary artery, significant mitral regurgitation, and severe disease in the left anterior descending and right coronary arteries (LAD and RCA) might benefit from acute PCI of the circumflex and then CABG to the LAD and RCA with repair of the mitral valve.",
"   </p>",
"   <p>",
"    In all cases in which a mechanical defect has been identified, we recommend immediate consultation between the interventional cardiologist and the cardiothoracic surgeon. Other members of a multidisciplinary team should be involved as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     As the primary reperfusion strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acute STEMI should receive either PCI or fibrinolysis as the primary reperfusion strategy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications'",
"    </a>",
"    above.) Studies of patients treated with either fibrinolysis or percutaneous coronary intervention (PCI) have demonstrated that outcomes improve as the time to reperfusion decreases.",
"   </p>",
"   <p>",
"    In stable patients with left main or severe three vessel coronary artery disease, CABG is often preferred to PCI (",
"    <a class=\"graphic graphic_table graphicRef61364 \" href=\"UTD.htm?43/4/44107\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H19#H19\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link&amp;anchor=H29#H29\">",
"     \"Management of left main coronary artery disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials or large, well-conducted observational studies that have compared PCI to CABG in patients with left main or severe multivessel disease in the setting of an acute MI. Our experience is that PCI can be performed successfully and without major complication in the majority of cases. The decision of whether to perform PCI or CABG as the primary reperfusion strategy in patients with left main coronary artery disease or severe multivessel disease who are unstable or who have ongoing ischemia is complex and should be individualized. Management should involve cardiothoracic surgeons and interventional cardiologists on a multidisciplinary team. The discussion should include deciding on the primary reperfusion strategy and subsequent steps after &ldquo;culprit lesion&rdquo; intervention if PCI is performed, as well as what will be done if initial catheter based therapy fails.",
"   </p>",
"   <p>",
"    We believe it is reasonable to perform PCI of a culprit unprotected left main coronary artery if distal flow is abnormal and PCI can be performed more rapidly and safely than CABG. This recommendation is consistent with that made in the 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    of Cardiovascular angiography and Intervention PCI guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who might benefit from CABG as the primary reperfusion strategy include those who are no longer showing signs of acute ischemia (patients who have stabilized) and have coronary anatomy at the time of coronary angiography that suggests a benefit from CABG as opposed to PCI. Patients with left main or severe multivessel coronary disease, particularly with depressed left ventricular systolic function or those with diabetes are examples. If the patient is stable without signs or symptoms of ongoing ischemia either clinically or by electrocardiogram, CABG should be strongly considered as the primary reperfusion strategy in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H19#H19\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259318985\">",
"    <span class=\"h2\">",
"     Late presentation or recurrent ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with STEMI present late (after 12 hours) and are asymptomatic at the time of presentation; thus, urgent intervention is not necessary. Subsequently, some of these individuals develop recurrent or inducible angina or have reinfarction and require revascularization with either PCI or CABG. We suggest using recommendations made for patients with stable coronary artery disease as a guide for who should be referred for CABG and who for PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H19#H19\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few patients with STEMI who have received successful primary PCI develop recurrent angina due to ischemia in a territory not reperfused at the time of PCI. Many of these patients should be referred for repeat revascularization with either PCI or CABG. For patients with multivessel disease who fall into this category within the first 48 hours after STEMI, we agree with the 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association CABG guideline that states that urgent CABG is reasonable compared to a delayed strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2860987\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic shock occurs in 6 to 7 percent of patients with acute MI (excluding patients with mechanical complications). This complication signifies loss of at least 40 percent of the left ventricular contractile mass. Mortality with medical treatment of cardiogenic shock in acute MI approaches 80 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiogenic shock occurs most often in patients with left main or severe three vessel coronary artery disease, but can occur in patients with one- or two-vessel disease. Although the limited evidence suggests similar outcomes, we prefer PCI to CABG, irrespective of the extent of disease, if it can be performed in a timely manner by a skilled team and if a mechanical complication of STEMI is not present. The full discussion of the use of CABG in such patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H36#H36\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Coronary artery bypass surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2860937\">",
"    <span class=\"h2\">",
"     After failed fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CABG is employed infrequently for revascularization after failed fibrinolysis. PCI is preferred in this setting because of increased risks of perioperative mortality and major hemorrhage with CABG, especially if the interval between administration of the fibrinolytic agent and surgery is short. In an analysis from the TIMI II study, 390 patients underwent CABG after fibrinolytic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients undergoing surgery within 24 hours of study, compared to those undergoing later surgery, had higher rates of perioperative mortality (17 versus 4 percent) and major hemorrhage (74 versus 51 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358599859\">",
"    <span class=\"h2\">",
"     Life threatening ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening ventricular arrhythmias occurring in the setting of acute MI are triggered by ischemic myocardium or the combination of ischemic myocardium plus scar formed from prior events. They are associated with worse in-hospital mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials or important observational studies that evaluated the optimal management strategy in these patients. Small series have included patients with life-threatening ventricular arrhythmia in the setting of acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These studies suggest that operative and long-term mortality (approximately 7 and 15 percent, respectively) are reasonable with urgent CABG and that the incidence of sudden death is reduced compared to no CABG.",
"   </p>",
"   <p>",
"    As life-threatening ventricular arrhythmias often represent ongoing ischemia in the setting of STEMI, our approach to revascularization is similar to the broad population of patients with STEMI for whom we prefer PCI to CABG. We agree with recommendations made in the 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association CABG guideline, which states that urgent CABG is a reasonable approach for patients with ongoing ischemia who will not undergo emergent revascularization with PCI and who have left main stenosis greater than or equal to 50 percent and or 3-vessel coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients in whom CABG will be performed, the optimal timing depends on the indication. Ongoing ischemia, cardiogenic shock, PCI failure, and mechanical complications are indications for emergency operation.",
"   </p>",
"   <p>",
"    The optimal timing in more stable patients with indications for CABG is unclear, with some older studies showing increased mortality when CABG was performed in the first 12 to 24 hours after acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/12,15-19\">",
"     12,15-19",
"    </a>",
"    ] and others not [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/20-25\">",
"     20-25",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    We feel that CABG can be performed safely in patients with post-MI angina based upon the patient's clinical status. In our view, patients presenting within six hours after onset of symptoms should be operated emergently to maximize myocardial salvage. The goal should be to complete bypass within 12 hours of symptom onset.",
"   </p>",
"   <p>",
"    Patients who present later than six hours after onset of symptoms when myocardial necrosis has reached its peak should probably be delayed for three to four days to decrease mortality and morbidity, including bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/1,26\">",
"     1,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with recurrent or inducible ischemia or reinfraction, particularly those with multivessel disease, CABG within 48 hours is a reasonable strategy compared to more delayed revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several technical issues need to be considered in patients undergoing CABG after acute STEMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Minimizing ischemic time",
"    </span>",
"    &nbsp;&mdash;&nbsp;An expeditious operation to shorten the interval during which the patient is actively ischemic or hemodynamically unstable is a critical component of the overall strategy aimed at reducing myocardial injury and systemic organ dysfunction. Thus, patients who are continuously ischemic, hemodynamically unstable, or having recurrent life-threatening arrhythmias should be stabilized and transferred rapidly to the operating room. Resuscitation should continue en-route to surgery, and unnecessary delays should be avoided. Aggressive use of pharmacologic agents and the intraaortic balloon pump is essential to achieve stabilization. Percutaneous bypass may be used in some patients as part of resuscitation in the catheterization laboratory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intraaortic balloon pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intraaortic balloon pump (IABP) can be an extremely important adjunct to surgical treatment in patients with acute MI and mechanical complications. For other patients, such as those with cardiogenic shock, the role of a preoperative IABP is less clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H42#H42\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Summary and Recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Type of graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of bypass conduit is dictated by the patient's condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the stable patient, arterial revascularization (particularly the left internal mammary artery to the left anterior descending coronary artery) should be used because of its superior short and long-term clinical results. Even in urgent or emergency situation, aggressive use of arterial conduits should be pursued if the patient can be stabilized. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H12#H12\">",
"       \"Long-term outcome after coronary artery bypass graft surgery\", section on 'LIMA plus another arterial graft'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the unstable patient, venous conduits are preferred. This affords a more expeditious revascularization and an opportunity to directly deliver cardioplegia, to control reperfusion to the acutely ischemic area, and to avoid postoperative vasospasm in patients who are usually on varying amounts of vasopressors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259318725\">",
"    <span class=\"h2\">",
"     Minimally invasive CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that both on- and off-pump CABG are acceptable techniques for patients with STEMI. An early report of 57 patients with acute MI minimally invasive (off-pump) CABG without cardiopulmonary bypass suggested that this procedure is associated with relatively low risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/29\">",
"     29",
"    </a>",
"    ]. In another trial, 128 patients within 48 hours of symptom onset were randomly assigned to either on-pump or off-pump CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/30\">",
"     30",
"    </a>",
"    ]. In-hospital mortality was significantly better in the off-pump group (1.6 versus 7.7 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259318798\">",
"    <span class=\"h2\">",
"     Hybrid procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to CABG in high-risk groups of patients with STEMI is a hybrid operation. A subset of patients with suitable anatomy may benefit from a minimally-invasive off-pump CABG of a left internal mammary to the left anterior descending coronary artery in conjunction with PCI to other significantly diseased coronary arteries. In select groups of patients, this can be achieved during the same procedure performed in a hybrid operating room. In other patients, the revascularization procedure can be staged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44296?source=see_link&amp;anchor=H113901358#H113901358\">",
"     \"Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues\", section on 'Hybrid procedures'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOMES AFTER CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous observational studies published between the mid-1970s and the mid-1990s reported early and late outcomes after CABG for STEMI. Hospital mortality was less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/1,12,17-19,21-27,31-57\">",
"     1,12,17-19,21-27,31-57",
"    </a>",
"    ] and long-term freedom from angina and survival were improved compared to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/12,18,19,21-23,27,33-37,39-47,49,51,54,55\">",
"     12,18,19,21-23,27,33-37,39-47,49,51,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the applicability of the results of these studies to patients treated since the introduction of PCI and the use of aggressive antithrombotic and statin therapy is limited. Observational studies that have evaluated in-hospital or 30-day mortality since 2000 have reported rates ranging between 1.7 and 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/1,2,58,59\">",
"     1,2,58,59",
"    </a>",
"    ]. The variation in mortality is likely explained by differences in patient selection and severity of illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526663924\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use of CABG in patients with STEMI are available from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association and the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?6/22/6505/abstract/11,60\">",
"     11,60",
"    </a>",
"    ]. Our recommendations are generally consistent with those made by these organizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"       \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the most important determinants of long-term outcome after ST-elevation myocardial infarction (STEMI) is the speed with which blood flow is restored to the ischemic myocardium. Under most circumstances this can be accomplished more quickly with either primary percutaneous coronary intervention (PCI) or fibrinolysis than with coronary artery bypass graft surgery (CABG). Therefore, in patients with coronary anatomy suitable for surgery, the role of CABG after acute MI is probably limited to those with cardiogenic shock, unsuccessful or complicated primary PCI, mechanical complications, or those with a late presentation (after 12 hours) or early recurrent ischemia. STEMI patients who are not candidates for fibrinolysis or primary PCI should also be considered for CABG. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.):",
"     </li>",
"     <li>",
"      For those patients in whom CABG will be performed, the optimal timing depends on the indication. Ongoing ischemia, cardiogenic shock, PCI failure, and mechanical complications are indications for emergency operation. The optimal timing in more stable patients with indications for CABG is unclear; the decision on timing should be made by a multidisciplinary team. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Timing'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients who present later than six hours after onset of symptoms when myocardial necrosis has reached its peak should probably be delayed for three to four days to decrease mortality and morbidity, including bleeding complications.",
"      <br/>",
"      <br/>",
"      For patients with recurrent or inducible ischemia or reinfarction, particularly those with multivessel disease, CABG within 48 hours is a reasonable strategy compared to more delayed revascularization.",
"     </li>",
"     <li>",
"      Life-threatening ventricular arrhythmias occurring in the setting of acute STEMI are associated with a significant increase in in-hospital mortality. Their presence does not alter any of our recommendations below.",
"     </li>",
"     <li>",
"      The following are our recommendations for the use of CABG (or percutaneous coronary intervention) in patients with acute STEMI:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with STEMI, outcomes improve as the time from symptom onset to reperfusion decreases. In most cases, reperfusion can be achieved more quickly with fibrinolysis or primary percutaneous coronary intervention (PCI) than with CABG. Thus, for most patients, fibrinolysis or PCI is preferred to CABG. This preference for PCI includes patients with one or two vessel disease who have cardiogenic shock, but are without mechanical complications, as the restoration of myocardial blood flow with PCI of the infarct related artery may take only minutes after diagnostic coronary angiography has been performed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with left main (as the culprit lesion) or three vessel coronary artery disease, with or without cardiogenic shock, who do not have mechanical complications (such as acute mitral regurgitation or rupture of either the ventricular septal or free walls), we suggest immediate PCI rather than CABG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). CABG is a reasonable alternative to PCI when it can be performed more rapidly than PCI. (See",
"      <a class=\"local\" href=\"#H2860987\">",
"       'Cardiogenic shock'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'As the primary reperfusion strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unsuccessful or complicated PCI with evidence of ongoing ischemia and in whom the coronary anatomy is suitable for CABG, we recommend emergency CABG rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'After unsuccessful or complicated PCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with hemodynamically significant mechanical complications, we recommended immediate CABG and attempt at repair of the mechanical defect rather than a strategy of PCI followed by cardiac surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mechanical complications of acute MI'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For some patients with ischemic mitral regurgitation, primary PCI with hemodynamic support may reasonably preferred to CABG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99780884\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Richard J. Shemin for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/1\">",
"      Gu YL, van der Horst IC, Douglas YL, et al. Role of coronary artery bypass grafting during the acute and subacute phase of ST-elevation myocardial infarction. Neth Heart J 2010; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/2\">",
"      Stone GW, Brodie BR, Griffin JJ, et al. Role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute myocardial infarction. Am J Cardiol 2000; 85:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/3\">",
"      Zapolanski A, Rosenblum J, Myler RK, et al. Emergency coronary artery bypass surgery following failed balloon angioplasty: role of the internal mammary artery graft. J Card Surg 1991; 6:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/4\">",
"      Craver JM, Weintraub WS, Jones EL, et al. Emergency coronary artery bypass surgery for failed percutaneous coronary angioplasty. A 10-year experience. Ann Surg 1992; 215:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/5\">",
"      Buffet P, Danchin N, Villemot JP, et al. Early and long-term outcome after emergency coronary artery bypass surgery after failed coronary angioplasty. Circulation 1991; 84:III254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/6\">",
"      Talley JD, Weintraub WS, Roubin GS, et al. Failed elective percutaneous transluminal coronary angioplasty requiring coronary artery bypass surgery. In-hospital and late clinical outcome at 5 years. Circulation 1990; 82:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/7\">",
"      Chiu FC, Chang SN, Lin JW, et al. Coronary artery bypass graft surgery provides better survival in patients with acute coronary syndrome or ST-segment elevation myocardial infarction experiencing cardiogenic shock after percutaneous coronary intervention: a propensity score analysis. J Thorac Cardiovasc Surg 2009; 138:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/8\">",
"      Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation 2000; 101:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/9\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/10\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/11\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/12\">",
"      Gersh BJ, Chesebro JH, Braunwald E, et al. Coronary artery bypass graft surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II). J Am Coll Cardiol 1995; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/13\">",
"      Ngaage DL, Cale AR, Cowen ME, et al. Early and late survival after surgical revascularization for ischemic ventricular fibrillation/tachycardia. Ann Thorac Surg 2008; 85:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/14\">",
"      Every NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of coronary bypass surgery on subsequent outcome of patients resuscitated from out of hospital cardiac arrest. J Am Coll Cardiol 1992; 19:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/15\">",
"      Lee DC, Oz MC, Weinberg AD, et al. Optimal timing of revascularization: transmural versus nontransmural acute myocardial infarction. Ann Thorac Surg 2001; 71:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/16\">",
"      Kennedy JW, Ivey TD, Misbach G, et al. Coronary artery bypass graft surgery early after acute myocardial infarction. Circulation 1989; 79:I73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/17\">",
"      Creswell LL, Moulton MJ, Cox JL, Rosenbloom M. Revascularization after acute myocardial infarction. Ann Thorac Surg 1995; 60:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/18\">",
"      Nunley DL, Grunkemeier GL, Teply JF, et al. Coronary bypass operation following acute complicated myocardial infarction. J Thorac Cardiovasc Surg 1983; 85:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/19\">",
"      Kereiakes DJ, Topol EJ, George BS, et al. Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. TAMI Study Group. Am Heart J 1989; 118:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/20\">",
"      Ryan TJ. Revascularization for acute myocardial infarction. Strategies in need of revision. Circulation 1990; 82:II110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/21\">",
"      Naunheim KS, Kesler KA, Kanter KR, et al. Coronary artery bypass for recent infarction. Predictors of mortality. Circulation 1988; 78:I122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/22\">",
"      Applebaum R, House R, Rademaker A, et al. Coronary artery bypass grafting within thirty days of acute myocardial infarction. Early and late results in 406 patients. J Thorac Cardiovasc Surg 1991; 102:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/23\">",
"      Hochberg MS, Parsonnet V, Gielchinsky I, et al. Timing of coronary revascularization after acute myocardial infarction. Early and late results in patients revascularized within seven weeks. J Thorac Cardiovasc Surg 1984; 88:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/24\">",
"      Sintek CF, Pfeffer TA, Khonsari S. Surgical revascularization after acute myocardial infarction. Does timing make a difference? J Thorac Cardiovasc Surg 1994; 107:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/25\">",
"      Lee JH, Murrell HK, Strony J, et al. Risk analysis of coronary bypass surgery after acute myocardial infarction. Surgery 1997; 122:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/26\">",
"      Thielmann M, Neuh&auml;user M, Marr A, et al. Predictors and outcomes of coronary artery bypass grafting in ST elevation myocardial infarction. Ann Thorac Surg 2007; 84:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/27\">",
"      Allen BS, Buckberg GD, Fontan FM, et al. Superiority of controlled surgical reperfusion versus percutaneous transluminal coronary angioplasty in acute coronary occlusion. J Thorac Cardiovasc Surg 1993; 105:864.",
"     </a>",
"    </li>",
"    <li>",
"     Rankin JS, Morris JJ. Utilization of autologous arterial grafts for coronary artery bypass. In: Surgery of the Chest, Sabiston DC, Spencer FC (Eds), WB Saunders, Philadelphia 1995. p.1909.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/29\">",
"      Mohr R, Moshkovitch Y, Shapira I, et al. Coronary artery bypass without cardiopulmonary bypass for patients with acute myocardial infarction. J Thorac Cardiovasc Surg 1999; 118:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/30\">",
"      Fattouch K, Guccione F, Dioguardi P, et al. Off-pump versus on-pump myocardial revascularization in patients with ST-segment elevation myocardial infarction: a randomized trial. J Thorac Cardiovasc Surg 2009; 137:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/31\">",
"      Gott JP, Han DC. Surgical treatment of acute myocardial infarct: clinical considerations. Semin Thorac Cardiovasc Surg 1995; 7:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/32\">",
"      Dresdale AR, Paone G. Surgical treatment of acute myocardial infarction. Henry Ford Hosp Med J 1991; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/33\">",
"      Berg R Jr, Kendall RW, Duvoisin GE, et al. Acute myocardial infarction: a surgical emergency. J Thorac Cardiovasc Surg 1975; 70:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/34\">",
"      DeWood MA, Notske RN, Berg R Jr, et al. Medical and surgical management of early Q wave myocardial infarction. I. Effects of surgical reperfusion on survival, recurrent myocardial infarction, sudden death and functional class at 10 or more years of follow-up. J Am Coll Cardiol 1989; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/35\">",
"      Every NR, Maynard C, Cochran RP, et al. Characteristics, management, and outcome of patients with acute myocardial infarction treated with bypass surgery. Myocardial Infarction Triage and Intervention Investigators. Circulation 1996; 94:II81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/36\">",
"      Guyton RA, Arcidi JM Jr, Langford DA, et al. Emergency coronary bypass for cardiogenic shock. Circulation 1987; 76:V22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/37\">",
"      Allen BS, Rosenkranz E, Buckberg GD, et al. Studies on prolonged acute regional ischemia. VI. Myocardial infarction with left ventricular power failure: a medical/surgical emergency requiring urgent revascularization with maximal protection of remote muscle. J Thorac Cardiovasc Surg 1989; 98:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/38\">",
"      Bolooki H. Myocardial revascularization after acute infarction. Am J Cardiol 1975; 36:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/39\">",
"      DeWood MA, Spores J, Notske RN, et al. Medical and surgical management of myocardial infarction. Am J Cardiol 1979; 44:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/40\">",
"      Berg R Jr, Selinger SL, Leonard JJ, et al. Immediate coronary artery bypass for acute evolving myocardial infarction. J Thorac Cardiovasc Surg 1981; 81:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/41\">",
"      Jones EL, Waites TF, Craver JM, et al. Coronary bypass for relief of persistent pain following acute myocardial infarction. Ann Thorac Surg 1981; 32:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/42\">",
"      Berg R Jr, Selinger SL, Leonard JJ, et al. Acute evolving myocardial infarction. A surgical emergency. J Thorac Cardiovasc Surg 1984; 88:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/43\">",
"      Singh AK, Rivera R, Cooper GN Jr, Karlson KE. Early myocardial revascularization for postinfarction angina: results and long-term follow-up. J Am Coll Cardiol 1985; 6:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/44\">",
"      Phillips SJ, Zeff RH, Skinner JR, et al. Reperfusion protocol and results in 738 patients with evolving myocardial infarction. Ann Thorac Surg 1986; 41:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/45\">",
"      Jones RN, Pifarr&eacute; R, Sullivan HJ, et al. Early myocardial revascularization for postinfarction angina. Ann Thorac Surg 1987; 44:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/46\">",
"      Amsel BJ, Walter PJ, Van der Mast M, Vander Sande J. Immediate bypass surgery (0.5-3 h) for evolving myocardial infarction. Adv Cardiol 1988; 36:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/47\">",
"      Collins JJ Jr, Cohn LH, Shemin RJ, DiSesa VJ. Surgical treatment of evolving and sustained myocardial infarction. Adv Cardiol 1988; 36:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/48\">",
"      Flameng W, Sergeant P, Vanhaecke J, Suy R. Emergency aortocoronary bypass surgery: late effects on infarct size and ventricular function. Adv Cardiol 1988; 36:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/49\">",
"      Kirklin JK, Shimazaki Y, Digerness SB, Kirklin JW. Emergent surgical revascularization following acute myocardial infarction. Experimental and clinical considerations. Adv Cardiol 1988; 36:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/50\">",
"      Vidne BA. Emergency coronary artery reperfusion for acute evolving myocardial infarction. Adv Cardiol 1988; 36:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/51\">",
"      Gardner TJ, Stuart RS, Greene PS, Baumgartner WA. The risk of coronary bypass surgery for patients with postinfarction angina. Circulation 1989; 79:I79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/52\">",
"      Kouchoukos NT, Murphy S, Philpott T, et al. Coronary artery bypass grafting for postinfarction angina pectoris. Circulation 1989; 79:I68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/53\">",
"      Curtis JJ, Walls JT, Salam NH, et al. Impact of unstable angina on operative mortality with coronary revascularization at varying time intervals after myocardial infarction. J Thorac Cardiovasc Surg 1991; 102:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/54\">",
"      Tanaka N, Mukai K, Ade W, et al. Emergency myocardial revascularization for myocardial infarction evolving outside the hospital. A feasible option when thrombolysis and coronary angioplasty have failed. J Cardiovasc Surg (Torino) 1993; 34:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/55\">",
"      Nicolau JC, Ardito RV, Garzon SA, et al. Surgical revascularization after fibrinolysis in acute myocardial infarction. Long-term follow-up. J Thorac Cardiovasc Surg 1994; 107:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/56\">",
"      Kaul TK, Fields BL, Riggins SL, et al. Coronary artery bypass grafting within 30 days of an acute myocardial infarction. Ann Thorac Surg 1995; 59:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/57\">",
"      Svensson LG, Cruz H, Sun J, et al. Timing of surgery after acute myocardial infarction. J Cardiovasc Surg (Torino) 1996; 37:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/58\">",
"      Alexiou K, Kappert U, Staroske A, et al. Coronary surgery for acute coronary syndrome: which determinants of outcome remain? Clin Res Cardiol 2008; 97:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/59\">",
"      Filizcan U, Kurc E, Cetemen S, et al. Mortality predictors in ST-elevated myocardial infarction patients undergoing coronary artery bypass grafting. Angiology 2011; 62:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/22/6505/abstract/60\">",
"      Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 47 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6505=[""].join("\n");
var outline_f6_22_6505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      After unsuccessful or complicated PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanical complications of acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      As the primary reperfusion strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259318985\">",
"      Late presentation or recurrent ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2860987\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2860937\">",
"      After failed fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H358599859\">",
"      Life threatening ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TIMING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Minimizing ischemic time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intraaortic balloon pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Type of graft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259318725\">",
"      Minimally invasive CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259318798\">",
"      Hybrid procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOMES AFTER CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H526663924\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99780884\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/47\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/47|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/4/44107\" title=\"table 1\">",
"      Requirements for primary PCI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44296?source=related_link\">",
"      Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_22_6506="Chronic GVHD buccal mucosa";
var content_f6_22_6506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73344%7EDERM%2F82463%7EDERM%2F61588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73344%7EDERM%2F82463%7EDERM%2F61588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticulated white plaques and erosions are present on the buccal mucosa. The findings resemble oral lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDVaYyHEYAz8x7ZqOS7RcpBv6YJbufSqkkiz5ChvmJxn0qlOChxk+2RWnLY9GNm9TQkuMHaTnPr3qJypBMDkN3BrLlumUgFt4A7j9KqPfbTlWb/AD2pOx0xi+hqzXaKSrkbhnjp+NVxfjJOQQehFYsl+TjlXwMc00Or8gBc980t9jRLl3Ns3iSLgvk+p4pGuFHGQT0rjb3XdOs5HEt4rMvGxfm/lWVd+NlKlbK1JJ43u2Bj6Cl6kSrRid/JfLHxnP07VVuL7jcCAoHUnFecS+JtTmPyNHCf9hKqTS3V7Nm5lklY8/M3Sp5uxP1nsd3da7ZxbhJdpnvsy2fyrMn8UQHIjgmlA7k7RXOR2e4A7cD2q/b6epbaMH6DpRZsyeKn0LbeIb2U4ggijHvzik/tnUQQuYwD32VYhsAVPAx9OtSrYqQC3rwMVSiZ+2qPqQR6pqTYBkAz6KKd5t7NxJO7ZPTOKurY7ZFJHI7CrcVoDnIw3eqUO4nOb6mN/Z7FyXYsSMktzilWxGSqg49a3vs3G1SSvX6VILXIAOVU9wKfIkT6mGbPYocjGOxPaoXtW8veq4zz9a6V7Esigj2prIsSkmJGVgVw3GD68U7DSuc3FFsUlBnjB4qMRZcu2G/DpW01h1wCCffrSRWa5KuAv+0eOadrj5OpkrafNkBivU8YqaK0BYvklRyBmtho2WMbgpz6HtTPs4Iwg+Ud6drCSuVjukQNtK9BgjrRLbsh8wIOeBgdK1Le0eSFSzbcc5qX7LIzqpKlF59CaG7CtYzhD5e0sAc+/WnwQLKXeYsgX/VqB1+tad3byQorJHuJOBVeO1kb5hgLu/Wi5ahcdEBIhA4HbNWbONWDNjHb1q3Z6ekUm5zuz2HatCG3QA5XaOg9aHcTS6GdHbEucg5J7dPxprWwEwZQcdcVrSpsQE/KM5471WlXeoKodoPH1pFwRmyxN8wkXCjkVCFVEYDGO/HNaIjx8pHzdODxmlaBCDgHOOTirt1L20ZizENuQglTz16VWLKuVbGfcdfetee1RcYBANVTZbgW4bHGKjlYaMwJ7De3UbehFUXs2SVgQMdlNdM1rtbZ3PQjqKbFFFvZZ0+bGFPSmoIymct5BGcg47juKkt49xI49ietdH/Z4mjZkXMiHIPrVa1s1kuwWUpk7WTHQ+tVyO5i2iPyHjhAYHpwQKy54JQ53ZUg8HHNdwtthTE42uBx3yKrz2CSx5Vc8YYVtKBgpGRpd0BFg8OBg1chvbd7ne69fkOOx9aq/YwrFcZ54P8A9es+4Vo3cEgjHPtSdRxiP2fMzR13Qkuh5sLj6AcGvP8AWLcwTsrjpxnpXZwajKsAAfKjjB7isPVts4kLDcB371FVxkrrcUYyjozgL9Ns+exFdl8PtL2pLqEoIVwUQ4/M1zd7bmThFJbOAK9d8J6XiztLYLmOBR5h9T1xWEdXc0pR96/Yz7+Bo2McyENwc9Mg1DbRboyoLHniuv8AFFkmLefBcY2MAcEemK5vyTFu8k5HQhhyKicOWR6dJ86uyq1qyNyvT3q1ZwuejjDY6nP6VKUZ1wxKkCr9jYKSMynd14FSlroXKOmpJaacCqNwwGTk96uwQLgcjvnBq1Hp7RqmxxsHJHeiC2CEGKQqSexrROxzyjcsTXAeTPEW3hR0xiqdzfSmTzCQ7juTmmXb5RlYbT9Ov41jXDMT94DJx16VTl2KjBdSWa6ViQd4P51RkkjPVnBHr6VXmkJOVyAO5NYfjGWSDRiE4eQgMd2SB6VA5y5VcvahrWnaeMyzl37Rx4LH/CuL1rxFd6lIVRmgtgMLGrHkf7R71hVIoJIpNnBOtKe5JEMmtCCLOPWoraAlhgZrdsbNsAlTnsDUqLYRIbS0ZzwMcDk1tQ2AIyQePWrthZY2ErurXhtyOGAJPbFaxgjXluZENrjouTjGMVq2VgWbCLtwMnFW7W0YS/KAec57VsWtqGUEYB9R/WqUCpRsilFZBUOQN+OPegaczMhAHHJGOlbMcKqeRlhx0/zxU3Ow7h14wKqyRNmY8NiuSWPzn2py2P7zcv3QeTitdBmLGzAHSpCFyWbJOPwzRYfKzNNsrHCgcDBPSljh2LhUwehJ5zV1t4iOBknkkDikEZ2AgKG9anY0UNCi8RVxtUH1PYVDPbkbN68DrnvWqsMgO4kt2wKl2q+Rsfgcgjmj0Dlsc+LcNnYSpPtwKikhX2IPGSa3JdPIGI/lDepzUBtSvA2ll9R1ouOyMcW4PA5x3qS1jJ3qxIGM9avmJJBgg7zxk0kUZh+bgkcnNV6hyjo4G+TcyfLg4HNWFh80h9pLA9QOBU8DwyfPlVI4I9anV137FC89Mf0osZtMrpalpASWIxkkilWONZGbAIHOBVlI2Ys0nyKf4P8AGpVSMlcqFXGMelJKwKIkflE52FVXIJxnJpsNuJvnJZUXIAB7+tSqg3ng7fXHWrSQqI/lwVHGM0D5SuYF2hvvdsE9zUcsCmNlH1bNX0hOz5M4HOfemTxYIZ2OM4xnFSxqxgPF5ZwecdGHSlZGILc8jpmr13b7N5RNoHLKe/0quNh2gnFVFm7s0UZABzz7ikMQbOOAKtSLiTC85FMKfN/d9/etDNqxWuLXbDvyMeneqkCrI22QAqOfQ1ozxyInzZxis1lUNk8A0zK3Mi/FDGm4An5TwR6ehqC/gTz4yPl3ZBP8qW0YsW2knPUVPcYkRNx5Xj61fNdHJKLTLFmvnogkAL4Iye9QxRFJHQA56896WznVIcE5xkHnpUqyrI6sh3Z6iq3VyEncyL6FlLOinB4xWZJY/aSWHyMF6GumuigUZPJ6D1rMlG1tyjocGoku5rHyOUuLCWGFmI+Q8E/41h3MjKxRjjPBNej30cM0BI4DferhtctBG+5QNucH0P0rCpBRV4mifNuYtlbBtRiA+ZS2R9a9r8O6aEsQueQMkj1NeXaTaxLfW7M3zlgNtewWEyxW4XOAR2p011HFWTsUb20+0mSDOAVxn3rmriwljxvGHB646iuyiG1Wl5LMeRTJ7d5VLMgCZzyMk0VI8x20W1qcQtuAx4dT6ZqeNjE4+bB9TW7LZgv833R3A/SqT2+7IHPPpWHs2jpupal2C4XyslvwNW0hOMgoTgYGaw1UwSgODs9+1bFrOm3cCAp5PrUvQynC2xm3qIcjccmse9iiTnLE45xV69nZixJz3zWPO6hydw47dhVN3YctlqFpHEZ1O3J67j2x6ZrE8dQ+Zo7lyoMZDjH171qxy+ZOETOW++3ovp7VQ8RR+do9+VBCuAinr3/+tV6WOaqrpnmIHzf41at48moY19RzWtp0AaRVI5NZN6nDFG5oGnNMQQua6uDTVWVQV+YjOMVo+ENLHkoXXHf3rp4dNR7h3HRQBmu+FNKCuSp+8c5aWmJBhcDOBWvFp2FHGcnmr0Vn5bfd78DrVmCNk3tJ82OgFQ1Y64u60M+OyCqSoyamjt/LycnB6cVoQhXiBC7ST2pTHzwcnn6UMpX2ZmSJg4XP59aRELyZY444NaCxg5JHJ9BTltwGBwMVm4tm6styukWOCcjGF7GpEtxv3c5HPNWVTaAQeT3/AKUBQWUtgZ561RBGu0ADgE9TT/LTIU/Nn0pTt8wkkAjpxxQwJJbHDHqKClEbsA5AA7Yx0pVXLZJIweoq3Gvy/LyB2IqNoi+SqrjofrQBQvDIR8hLMDwRxVbFyzEyw7RjjBrZS3IcEKoYDj3ppRwCTE24cg5yKgLrZGISTKsbAI7DqemKclkpVs/OAc4Y9K0mjbbtK4kJzz2zSSxsU2A8DqQKZL1ITaqVwiL059PwqpBbiKQYwr8kBuABWjZrk4DYjHAU9asz22CCQM4yvc07CWjsUEeTaOCD3+Wnqv3NxAPTjnn3qdEZkbO0OehP86HjEAQdG7kdKRonrYaCyHaBuz6VYjJjjYHA7k4p1qinpxjoe9SiMBiCwbAwfc0EN9BkUzqfkCsuetOB3seQc/lThCmzJBGPU8gU8BYkUrhkAzSdhWKjj5DjAYetY8yAS7xH7YNbUm1iwdceg7fnUU0KsCuVP1qHuXF2MJnCkbgVz0PanB1IDEjHcVZvbAMncMe3rWXPZywESQEkd09aqNRrcqykjXyk8Bhk6kdfasG6hxuZCWC9j6VNBeByVbOQec0tzEzAeWce9bp8yuc/LyPQzbe4jikxkhGAOT/CfSrzEvEGUjp2rNkQ28jF1BU/eHp7irKOAoWLbtHIHpRF9DKotbkLtJbykv8Acf0FX7WMXC+YHI6dOMUyRRNuCYIzkUmmMIWYMeAelUtGZvVGpNGj2xUjDYJB965u7lbayDgg4KnvXWeWJkyentWPqdmJs+XgMOnvRPXYqlJJ6nNyXbxqUZjgDpmsXVbhJU69iCBWvqFq6/fXJI4IrndTUiIfJgg/nXLObSszo5E1dBYS4MbAHzARz616ZpjyTQJJIRz0U9Me9eXaGrPfRxsMoOQT0xXp2mSo8Hly4IAwAR2o9p0KoUr3Ogsyqrucgv8AWnTT7Vwwz2wDWSqBPmhY/wC7mpPNLuueD3oU+52KkuhPNG0gzuKnvikjs8ISeT15qzbkP6ccHmnSybcjgjHApvuN32RjX0Y4Xr7UyOMybQrfdyAO4qeUCR+c9asWwZJRIhUN0wR1rKTuU9FY4i9mdmZU3kfzqibdyP3p2j65NatwxAOGIH0qkSATjLHqalJX1Mpsj+W32RRgmWQZbHOBTdbUraww7QVb52P8hWxpmltg3Ep+Zjk59KxzL9qvZcj92zHbxnvgVslbc5Z67HAXdn9nvpEHIzkH2NdZ4L0n7ReI7JuzVXxTp/2eW2uFHDfuz9R0rvvh/beTbxTS4O/7uO1VRp3qa9Diq+7HQ6yz0h4pUMY+UL0rWiEEKBGwJDyc+taECoVXbzgetQNZ7rwuxymM4966pPU56eu5VaDbMAoGAMZpzWW8gBdp7mtB1G/5h7gYpyN8+OmevHU1m+x0xk1Yo/YliiLEKVHWoEhE2FVAqr+da08ebXHfvUcK7YyMAcdD60jSMr6lG3sg7KxJCjp70+eBYgCOec/Sr0NrtYsWxnoPSq16vl7gGzkdO2ak0Tu9zOlI5IHU1E2d3OD2/wDr06U4bj9KryM3fOPWlc6YxFMmCQBz3OaenJyuRj19ahxk/Muc/rQ8xXCKcHPfpSubJX2NCEHaTySe1aUUO6LKphjzgVmWz7jwBz6HvWrZyFQQVI9s1Ry1E76ETRNubzlxx1qlKWHzRE4z0P5VqXFyrRlGwcjGBVMwruAO4g/dx2pEwfdGZPNNtVRHsIOOnJ+tPP70gbXJPUVfa3zwGO/0bniohExyTkEc8Dp+NLUptdCr9jXczYfJ4O09KjNs23hnLngVo7NuN2d3XOaNpCj+H0OciiwcxlQLJE20/MO+eop8m1pBtYqM9c9/TFac1uo3KdrYOd69D71myQEXAKZcA5AHrSbLjJSLWxkz1Zjg+4q1GQFyxUkjJPSq8SSkr5gJ9vanlMSBo8ZxySKV+xO5JI29NhOAvQYwabhYkweecinY+ct/EO5GaWPl28xgx7DH8qGh2sirNJmXeOQOmRULSbgM4Ynt0Bq7OhC5kXJPIU1WSIYYsyKc4APc0irKwz/lmAykc5B61TnQFSWHABIx/hVy5i3AFeSOOv51WnSRSWV9p7d8+1O1xKJz93AEKsq4B5yDSo7KB0I9fSrV0hxx1PYniqIG0krk7utVF8rFKN0PdGmVhKEI9elZki+RL1/d+hrTO+Nisq4XHB7fSqExEjDgk9CBxWjsc1tyS3kWLBQ7kYcEj9KmjCyFdhKNng1QhQJuCkknjBOauxKRIMjABqk9DNo1ilwkQClSD3qMW0mWDtg/w4NTafdFM9l6jP8AhVv7VBckBldSeNwoI12scbrEMsTsPvE9T0/CuZ1CMHI2kDv7V6nfaTC4LMSf1rj9WtEViACw6DjrWFWLep20JqSscnphFvMCemeuOldfazZQEYxXL3cJjbIXaD+NXNOuj5eM49c1jBp6M2TdNnX2ExLY7/pWhG3OcDPp1rE0vLoHJ5PQVqqwDY+8B1x2qttGdUNdUXoiRwAMnuDQ5AI/WkhYdBjntSyHc452gcDjOTSb0KW5C0Z83I6DHSrUUfzjcDhucinW0DPIGkHBBbJ4yBWtp1orKnmZDbwBx0HepJqSSR5RdStLJ5cYyOmfWrVvZ7YhkfMfvHrTreECUZGTnpWjIvyqVHGP/wBdXTXVmFRa6FmRiunTIihhsOMdQcVzVjaC2uSHbKkZHt7VvRzr5ZXGazyVV8kdeRitnumc/K1cx/FaobGJCPmEy4ru/DGmP/ZdsSRnGcZxXH6zavfwgRkCRWDJnviu98JanEdJDSA74wFZT1DelXD4mzirJ6WOq09SkQDgs5bHFaTW+4ZBOe/tWdpUyzIHI5DdK1pLuKCLL5Az070SZz2adkVGsm2E87uo96qlQp3Hg9MjrVq61NGj+TJZug9KpSyEOGI/TipubwT6gzZU5yQDnHSpIHHGcNj1quH+f5jmo5JBGrHJJp3NVEuPcoGxxu6msm7mMpbIwP5UySUEE5INVXZnbAFK51QppajWfqP1qPk4U5P8qmCFTz3oCjjOcUjZSI0Ptkgd6j+zvJLuZgB6L2q2I8deueoqVUyrMRila41NrYLYDOeSK045T5QTjB9arxxbACuODViGPexUZPcEUznm+bcleGMj5ehGaTayuMjIPQ+tSuQAo247mnTOGO5TtDdvWmZq4JEJASiHAXczE8DFRiPeG2DCgcjNOjR24LDHXjvTZFcH5X3DqTSF1tca9sHB6naO/NVXTytwzhR29auJJjqckZ4PSobv7hyMseOKljje9jPS6aeRIvkVFbqTj860re23Wv2rZvgDbPkPJbqOtYywEltzBWGeCKlhuJ7ZJFhlwZRh1wOR1/Clc3lC+kTRZWZ1VBmRiRtxyKgkjeJ9zrgdCP8AGptS8Qy3qKlvawQyc+Y8S48zOOvp0qgpZtpbIYcDPJNLluKMWtWSlzI3zbVDHO0dBSoCxJUsB39qQIBgMeBzmrEfA+Zs46YFWVKSWxEwyrPjGf1qMxByBgfgausynIABPqRUXyjkDPbp0osLnM+aPaxUfgarPk5z0PatGV8Hdg8flVeQoQSOo5plcxk3EW5R129fUmq8Fo0rlgAADyfar1wCj9CR6in26LjKjaere/vQlqRU0WhDcQAowZe2cjvWC9ruuAFO09Qf6V10tuShYDHFc3qSyDLdDnkjjPuK0kjkjqZlpzcEP8r5IIPrWq0G8KAOpzn0rJUMZmdfmOMkmte2mUBNxBDDIpRd0KorMsWlnJvClSR1B9quS2ioVYIcDr7UyO+UbCpAccVqWki3UHmMQJBxVGTk+plXW7YMZU9evWsHUEkBaSQblxxhe1dReoxGI2G8dsYArDeR2maGaMehI71LVzalJrVHKX0TAYIGPTFYF0Gtp1YHCMea7HVrBwSVLbB69a5q/ijZNkmSOvHrXFUTTPQSU46HTaRcI1vGyHOeOtaMbjcATgjrXH+Grgwztbuwx1B9q6hG82Tg5I5x2q+bmVzWk+hrQsHCk5A571Lv5AB47j0rPDlWUY7Vtx28OFYuWDDIbuKi9zd2WrLMLefGDt3OoG7AwBz6VpxqZFLKxEmASOvbms6xAhkcDI3Dr6/WtO2ZEDs67cg4ouc9TyPOzEF+ZhinJt24XgN6VI3OHmHB+6SahPXK5x7dqakbShcgljIchTx1pkgATIz9TU8mM46cd6gkXIxz0xWlznlGxNaxAyDcM0ltci11xokyyyjBHrRathTj7w4pbCEt4gtXk+7ux+laQvpY5KlkrnqGhxtFbJhVAx3rTlhWeLLjjGeKi01Q8CDHyjpj1qxImFODk+nWre553NrcohIhGdqDJJ5qs8Tb9xPHoKszDEgUHacDNRXBGwgEDBosbJ2ZnPPgkEgc4/CqNxKzgAH/AOvVqcANkY5NUZss+DkLnjNS9Tqp2J4lJGSePU08x7WBPC9qntU3KMggY/KnOpBGRkDrTsUpXZRKEsPQnmpY4yMEjAPrVhIc8EZH6mnMMZwPbFIvm6IakR4IGMdvUVMsYG04zzihFY4J4NWI128ds80Et6AsWBwRuBwSetPtwVII7d6CSB6npxUiuAvA49e9MiWxFOWLfP1z2p6IArFugGSPamkqXyfrmkiXzDtC5wenrQV0J/IaNnYnB4yhP40SOGC8Ac8jvTmd1Ujoe+Tzj0pPNIICLkEbfekQ7iPEAeiqQMgr2qtcIxG5j7gdiKs+eYVYY3gjgHqD61FKytGeScZB9qBRvcyLq5WAE7QOc9Ov0qDTtswldvvdST2B6VFfM0krKCSo7njA9KdpnluilgG4wB0qLHYklG5pIihO2z1HY1KsfBP8XHWnwxAbd2OO+KmQFiWxhM4q0rGMndld4iC2SR7EdaTawLBsnHA9qvSDEZ3K209M1BJEisCDknqfSghSuQ7cZH8XrSTDLHJp7+itkdaYRkDOaC0VZc5A9v0qq6jvkZOcetXpUxyAaruh6daC0VZGXHzLkN0I7VJDKkpjBYbqimUhQQOfamtFlFaJwT3X0pkTimXZGIhYc8njNZl3GrM2eSB3qwlwj/JKTwOe9VLqcIX4yueMVVzn5Wjn5yI5WjJ2lh+FBUgq646ZyKfeN5jMSFLe4qohZWwACuMYFJOxcol5XYc5zjn0xU9ne3CTNjBQjtUUZDbTjjuKtRwqxIGVI5GOtUZWRYa4c5KdetJDI8gYy7S/+yKYYFMeOCxHHNNtEaORsp+O7ii4klYfd3MKxFJY1OR+dcrqphmXYYYwM8EDmuyjjg2ZmiIB/jI4qhf6RZzRs9nIN/B68VE48yNqNSMHqeXT+baX4mQZHcgdBXZ6HJ54DtznpWXq1i0TMJVCv0x60/wbchYXhkJDoSOnIrjinGXKzvi1ujq2UOV3HAB5rbsWkZ2txFtIXqT2rJsYvMdiDleDg1uQwthpF3ZB3A+3Oaqxs5K1i9BDGRlC2D97P5CpYIs3bBmby+dgPakSP5UI5BG4le1XAEMZ2kbemW7Dr1qWzlkzkri0AAB3iPHBPrWQ0Ox2DEcHqBxXWXkDXEeeSCOgOB+FYt5bqDhSWPf0o2Z2Rd0YkwZMNgfWqrZON2c+uKv3Ay3XjOaoTkAkk1cWZVEV5pDGykcZ61Po2oOmrQshUkKc7iOmMcZ781mX0heNkBIP8qqaH5r6h5pAbbgc1cJ+9Y4q0eh9CaDIg08KzfMOuPWrXmKFLE4z0964nQZLt4VbOxXwSvciukVmAyVDY6LW7PNdPlZJfjguPvHoKzJVcAmT7o7Dpmr0Jedg0n3R0AqG9UySDB+Udj0zRcqL6FBh5md3U9B6CqrghsZye1aDRlWBbgn0pDbiQDj5vehm8ZWFsziIDBIHapDy5UDgjk+lNRDDwOvuakXru7mhDTs7kbhgu1Tgnv60IrbiSfmPrT5Ew3yg4H6VGrruAJ+ox3pGqd9iYAKMkZJP5UksmCB0z60hYOMr96gIfkDDjsaBoa0jLgHJBGOlPR/4gSR9OajlGCo5JxnPpTVwSTk4P4UFaMmkk3MMg7quWaOrLLFJtkU7g3TBqkFGQxO73xzRE7xMShyPT3oJfZF7UJLq5mae7kEkpABboTjpnFV1hJcMj4GORnkGmpKW5LZbPJ/+tRuO7JGPXFJaEWdrDJVMbkqGzjBHWqc80oLCMNx6Gr5JI4Py9z6/jVaQIEBxhj1HqKCovuYEzySzH5XRWPJxx1rVtIFjRTGBz0zyKZcR4jJTG3PIB6UmnyjzFQk7R/D2pHQ5Nx0NmL5QPlxVmEqsyfLuXOMdhVK3fg7evqRzVxMALyM5qjml2NG7USxMOB6471ktGVRlXIUetWJJ5MkZAHalRlkjbPBz+dKxEE4ryM903HdjJ9qUKc5xkCrewY5GSfSoZUyGBztPGelM3TKz4ckNVZ/kJ5xmpphsTrk+lVJZCGUEY6+9I0jFsa6hicDOKpvEQcjgAYzVtiQM7eDQCGPzZB/lVIl6GVOCMKDwepFMZHkj2/ezwCR0FaptTIMhQTnv0pY7UxnD5D+hosZykraHMzWb/eVWx3GapMGEnzDkdRXXTxOuSinrzgZrNubUTtucEP04GM0WFGV1qZ8J3E/LgjvUix/OrDAPfGauJaBeVJ49RSYaMncuc89aZNk9iaGRAMYyO+B0qwhAGVOR9KgUBU81AGXvx+hq5Gsc0YkUFcjBFMylFC4WVeNr46is+SAI7tECvY1cWzeJ/Nibcq87D/jUytHcRkAoJV6qT1pEN8uxx2tQedG2QCR6iuPkEtldCdPlIxu/2hXp+pWqFQVAGeua4vW7EoTjGxwRketc9andXR10K32WdVpEqzRwtGRllGD7V01s+5F3RM7Hg8Vwnw6kW5L28znfFkcnHsK9FQLyoblDtGT+fP4VmneNzebV7IegZUdFTcXJBLdMY6fnUkMDImySIFcEgEYGKntHY7lZcE4xx+ualln8tRGhDPyST/L61LMpSs7GLcouPLCjhs887gf8Ko3ygLMgC9eT6V0VxbKoWWRQxPG3HIGPX6Vi3dtIoX5sEjbt/DjNUdlOaZyV5EC4ByAM8dKx7xD5DEAHHSumv4vLIz17k9qyLuP9304YZ+tI6ZLmRyU7ZOW646Zrb8F6cbubc3+rPzYzWFqEZSVlJ6V1nhe4+zQIgUMT2xjNOj8WpwYiL2R6LYIEiCjtxxwKuGRDgbsnp6YrLs3mnVS5GfQCreJnXbGNo/vNXZfueXKFnqWDIkSYzuPoDVcSlpRkcjoKYw+zECRw289ehFTxIu4lc5HcildBawqxHBd+SewpyqM5yM1OFAYM4yOmKaRn5ioHoB3pAU5xk4x074pEbZjaOOn1qaaI87uSOcgVSJYHjj2JoN4K5PIcj5eh7ZprY2hdoDZ65psYIyXGPY04EZ5ORxg0GhKm0EDHzdDTZWBXJyVzk+1SAqMkjim534IpgRLJk479fSnER9c8/wBaWRGCMUC7gMAt0z71GVct8o5B6Uhpikgk/L9eelSR4OCCFIHGe9JLDIPnXg+/INV3BK/MflPvQNWZOrESHgdORTjnqBgEcgmqsTBThuB0y3UVaWNmICDt0NNMUtCNnAyDj6elRO7bcZ3Drj0qcwgKRICrjpk1SkbywCRsJ/I0MIyTFKjqRxwQPWmwwbrlBnApqTJj5gdpPzc81Ytn3uhU5y2QSKVi22kaHliNcdAOM1KNvPzYYDpj9aV4+SiN5nRvl5yPf3qzaRSNfTW+nOZkYlN+MblI5xnp0ND0MFK6KhAYjI6cGp0A3kIQyjqR06dqrySIqoqPlCx2A8EfWpUJJ+br9OhoKkOnOCAMAVHIwKHqB60yUu0gJPA7VG7YzzyKBpaFe4YbiSMAjk46VX2FwcDgHvV7h0yBx6etRSREggAA+xoNVPoUWI39OfT0qdY7dlEgcs2MkEYwfSq0ynfl88fhSKX7McHjH+NCYpK60JRI4bIJwOce9WyxlIZlCt6AcCobSFmIZgcHkHPWrRSRWBTa3ba3Q1RhNrZFSVSrHJBHbFU5E3HgAnt2rU8gnk4B71BNAVPH3fWmZpoycsz/ADJgA9adJbxvncMH3HaluZkt5MMWPfjpViKVZQCOfYmlc0cXa5HDF5MeEOV9DViIoVJBUelI8kZPlkiq66fLLcL5PAyDnPQUXIcb7lqBxFIQ5G3qpAplwkbZ2bQx7gYrQa0XyyQPmx+JrPurLhjExAP60znur6GDc3xQsko2sO2etY9/MrqUYA56H+lWdajdZSJuq85x1rm72UfcLYJyU9Mj096ylLlOmNNNXQnh6ddO8ROC2El5IA9f/r161YvGD5nPKnGegOK8VupQJbObPz7tpIPXFexaNOk2nW7Kp8woB8vIJ/oea54dUb1JaJs2VhkdQQflkIyR69qsMscDbXDEgZIPBJx0qRiJrOIQzxRui/MrkqAf731qrqLCUgpIWO0KzkffI74pMyTuWGJYq8aAsp55Hb1qlqO0s/lrkDBUe9assEkfzA54wzVTMGCAuzcG53A8+1C2OiE9bnK31kx+ZxtI/hPb1rF1GEqr4IIHA9q7S6gJDmVSWOehzXL6lCYw4Jzg9cUmehSlzaHn+pQHzM5JIP510vh63Z2DOMHvj+Qqhf2v+kquTsJwW/nXT6LbKXXJ2oAMfQetFPcK0Vqzr9OiHkoFUgHk561qp5aAk/ePXPQ1jQ36RkIoUj6cVN9uDBgSAx7DpXXc8OdGTepJepDLzIoK54AoEoZgB09RWXl3nYGU/N0Ht7VqW8KRRc8se9CHKHKtRxlUtyeBwT1FPjG993ROgHeobO0LufLBCjue9a8duEXA5pmUmo6Izblg37tRxnmq7w8846+ta32RFZnH3vWoZFCtsVGPvjj86C4zS2Mrcxyqrg+ntRtAj25GPftV6WPBIXbkGqcqNuJxhe+D3oOhNMDIG+UcGhcrwo4pVQkhtvI6kGkzg5OzPpQUTgkKMrighQcgZz1qvPKcHc3bjtiokm+bgk59aLi5Gy6GUx43fjSSRRlQoAyfXsajV/mHp29qdvySQOfUUyLW1KUkbK+SGOT25xU8RbsFPapXDMCXUHH51HEhz8pIA7GkNu6CYyLIrFWPbimvAvmAynKnrznFWpFZ02oV57kVXMjGRI3GCe9BmmV7uytym4EjB6KKrxRGBhKoYonJHeugXbxkADH61L5aPExXDAD8aNhKu1oYkd2ZXUwFkPGRnkVKs1xDJvjldHIK7gex60kdk7TngIFPOR1q9d2xaLCcY9B1oZfNFPQpIHUjkE9gKsROWzt3ZPGQeapxwyOCojbHH3uK0LWDymUs+cUXNJWS0HtbSEY4J+tNSzOQJCM/nVprpVfGVPt6VWkuvmJXORSvYzi5MiuVjQcA8dqru25OGA56U+d/MJJNJbRrv+bkGg2UbK7IBavLllORn1qvJbMkqgrx6dzW1HGqE7eBmq91HvIIIyO57Uxc93YbEAIty5wPaq5vtswUoNp456mrdsRtGeCeCM1JJBE0gd1GR04609zF2TdxIyWOTjB6GneUGBB5p7JwCuAMVDNI8asyjt0pmVrvQpXmlR3Ay3asu70/yYi0JORyRWi+pkhgVw2KoS6gzuQ+BleQKl2R1041LWKdquXVmfDDtW3bXCqFySSTjIrBdieUOBmqr30iTlACFU1Dmom06DqndoykgEnr3qteHaM4zj9axoNUkVR5gPrk1Yk1BZFwMnPH0rRO+p5sqDizE1NEkm3JtcH7yn1ridbslglkA/1MgyQP4G9RXdXlsrAtEcOe/Y1x+o+c0zhxyvG09TU1YpxOindbHE3aywxxLNncsmQwPBBHFeu/D+7Z9OgLyZIBAweg+teVayuLd8fdHzKO4Hf/ABrqPhrrAjukimaIxg42y/dPtmuOHuz9Qqaxsj3eGWV7WL7O0Cgr8x+XlvxqrcGQSMJmRpiMbsAjGOOlVre+tjAjJaQnI5C5zTLmcSgMsKxjP3AcitHuZQZrTOXAZZNwzyAcA1K6bwjbgrkZxnk56Uw2wiIljGMnBwRj8qkGx3XzDtcHlsDt6e9I322Ktyi+W/JAJ+XPcjvXJ6xCz5P3UTlc11zqzv8AvnYZB44zj396ztTsftCM33QgGOM5oOmhU5Hqeb36YdW2kqGGa1rZSsZ9cfnUeqWrRs4YcZ5NJDIR85AYDA/GoWmh6E9dUaca+XDy+ScHAqRATk9B+RqqrllB4BPH/wCqpYkl3Av0xgc10ROWUdNS7Zq7Tl0GcDljWra75XwQ+BxVSwQKAS4z2FattIoIxjB/WtOh59Zu+iNKGEJGFHT61KcLjoBjiqvngKNuCaUsyj5jjvg0HFytkjkso9jVSWYhwoUH+lWQ28ZIGaasahiSOfeg0jZblUDI5bLDt61E5XngEnqKtSADIHJrOuVVFypIOeaZtBXIpG2kgkAdBURQsedw7jNKfv4696duA5OdvQ0HStNiu8bcgk5pgUg4ZcVoPCGj447jvmqxiZT909frSKjK+gqEgEf060KzDqcZ7in7evt6UhXtkc/kKCHYe4IGQcZ9ajaTbycZA496mBQoBu5FIFSTaM8g00Yu3UiE64BBYe/am2+6WXdG3IOc1b+y4jG3BPpio7S1aNCY3w2eQx60Etq2hJ8yuVmYY+nNRxXAtpieWVuoBq+LRSpkkYlm7EdKoXVtskXLHB6YHSgmEYy0ZeguFdi4Xg+3eo7y+k+6kfPqRUcMZAJQfKe1TSQs59wOg5pFKMVK7KJmmZsk7D9OtSrkDc5yfU1cht8H5h1646ipfswIORkGkaOaMl2y56+9RNJgEc5q3dwtGTgAjtWXJuDHj161J0U7SRMHyxXdyO1W4omcYGPXrWbb53ZbGfbtWtaACMuxwKcbiq6LQfGGjT5yMnpmnMFlwy8kDFPaLzFXcDgjIwKbDFIj4xhfWrObR6lZIDGxd2DA9sVNKVUEKen5VYuLYLC7KSNwya52XzBlRkZ96LlQXtNTQkucONj4YdR2qQsW5yMntXPJZTHUdokaSNCCXHf/AD0rZuNoxh23L3FKMm9zSdKMLJMpaioD8rnIP41keSN7bRyeOlb0k0ckZSYHB79Ko7YskKxDds96T3NqcuVENhArvhuGH97vWommwOwkMSBgeuKzuUfnqK14ryIoGzg45B55ppGNZy3RWvUjjAQ85GQK529+VcIeRnOK6q9gS9iwMg9mHUVzWr2rW7Juyw7Hoc07uxFF306kNvMYofmGfrWH4gIkKNEv7xlIPbPpVj7WRlXGOetZ2oSnk8enFPmTVip03CXMcfrTNFglmA2lOf0BFZugXfkXsb5HB4JGcVoa7MrLIrDllP5jp/WubtZNrqR2PX0rgqKxjfU+i/DN69za25VdxPYAknBzW9NLFx5ayRjOG8zrn0x2rjvAOrw/2JblZG86CHyfK2E7GJ5k3fT8a628mDzho5VYRqqlm6ucYJxWqd1cy2dkdOix+W4J+fsPSm5hZmDAIyjIzyOO1Q+dIBz0BAzjrSNLwAIQ54zk4xz196R0WJ4/Jd+d/UZyM8+341JPvGNuBnpgc80kToyfKu18kYJzxTZFBIdvmOQAQSKBJ3OZ8RaeotHZGBLHB9/xrmLeMrGpJ6EhsdM5xXca9ag2wJkO1cnB7n3ri5I2EapF8oL5x64ptHfRk3HcsQP+9IOCq9/T2p0cdxLc+bkrF7n9KjhCqRuJLZ57c1bkuBDGSdx9FFWlpctyd9CzCrltpP0q3Bp92J8h129znt9KztOkkfDSLtycCultpWk+6AQOpxVRszkrOUNhFVogVT5j6561EPOd23MCvWrkcAjYuz7s9sVDO6K3UZJwFqzkjuSRSEFQ2d3XA6VYMny5Az9apRyxgk55/lQsrO/yLnFG4OF2TTuoXOccc1mXTh9oDdOTxUxtbqV28wqVbn6Uy5gEaF92ccHjrTNYJR6lUFsgY4x6dKUL865HQ04dgDVu2tyVDSDjqBQatqJMFUIOORznrTHiDAYJI9qmZdo+Xpjt3pYgTjkkjnmgw5uqM9/3chQ5DfT9KZLgjbn8hWpcW8cwO8EHgZBwarGDYQkYyPc0jRVEypC3BV+vYntUsaEHkD61I0DebkDp04/OpGQqchflHNMynJMYZAgIJ/KkjceYB1B5NMnlHLHHA6dDVCO4ZJAQ2D06U2KNO6N2eXAQY/iHINQXo3jeMgqc8DrVMXRkI34I6H2rQCA2+3cSCODmkJR5CvayIoYnLZ6YP51atznceQc9PaqWW81nbBY8kYxV9mU7SMHIzx2/woKnZMsYw43Y5HaraxbwNnFU4AN446dPStCPIweBSOaTsULm23A7sHI6VhXlsV5Pb0rq5cFOcEkelZF9A2Plz83FI2o1GnqYMULNg7up5GOSK0EQAhWPy1ditVWME/5NMkgYxgZOCevpTWhs6nMSfakQDGdvp6VOsiSgD17+lVGtHa3RCUCqSSVHJz60+Xake3gHHfvQYuMehdeFJ4NjMR6EGsfVLBIQrRcdue9NN60IIQll9+ag+3G7BBOT6EYxSua06U4u62KysyNkHacdVoIaTrjH86huGKMWT6YqLzzkEnKj36Uzr5L6otbBKdoJDDue9ZzWxiuTv4Ayc9cVbhu1mOCwBHP1qGaTAYtzu9TSdmVFST5StKQrMVYlfWot7FDtOMHANRTyhQwUH65pkcpwSCQDyfes3LWxtyaXNvRZpSmHOQOM561Jrlt9ohBXkr6d6zLO9EZGB8p4IrT+2K6Zz17VrE86tGUJ8yOF1GLyyVO4FfUdKwbiUglWfLLnn1Fdbq7LJdOQvHTGetcv4htHgRZyAqN1wKiW+hrKfu+8cfrDo8M+c70BKkd88EVzls3IArT1B9yTuXGFBPSsW3J3DH0rnlqcU37x7t8N5vO0KOK1niVVtWjaFpAp87dncc9cjoa7G+lWWVGWVZH8tVZwPvMByR/jXm/g1nj0rTfselWt00ke57gwljv3H5DjoR7+tel3dvF9jncxRW7xrGR5XZiOUP0qo6xIb1OqRkiOXRGTGAucgfSnoVbC4wv+yPvVD5w3AtH8q+n+PenwTQ4CSNsUc5zjH4e/SpOi+lx7nacbtxz1A5+hFSquZVw4YjO5d2B/+umbv3m4KNx68jn0+lSqFkwq8MOoPrVIpGbq9us9rKpzwp2jHPHOTXCLP5lv5kPJkYqM/qa7/VnKW7lSu5I+3cmuBuZkhCKMAsvCjjb603odVB9AgYR4U9Qfm9vrV0OxJLHdjoDWRbSjcQrDk7j3zWtZsSpLY5604u51SVjQgBKgPgscVpNdC3UJGRnvisKW4aOM7TubPGaktyzRgzAFj1U1al0RhKjzK8tjTn1OTYuOAfaqjlpyWMpU9uaURNNIgxU6aTLIwdWAx0yKerJXJT62JtPVpJmLnJ4GfWtZIjGOOeOeOlN03TnjQSOST71HqF0YJxGuOVyc9apaHFOXtJ2iTXDlY3ZAWYDIB71k3Dl40Jfgn7pPNaMc4kiyRtHUc9apz+UWJABGPvYplUlbRobbw/LvwSo71dt0Mh3An1HtTbcYQAcZHJzzV6GML8w6AUyKkiKZWVMMcE+1VoQ+4buCPerL4Zjjpnp6U1dqlem08jJoFHYVpAflOd3oBimmIkAjkn1qOZlDlgcgd80G7MaKZUA3Dcuc8+mKQuV20JViYd+9Ur2XyTyMA9RWr9oQLyy56VialiS4XBLD+VMKSvKzBZUMh3gFSOuORWfNF5bkpwAe/pVkEYITdxxk1SnkYEgnOevGQBTudVOFthybt+Pl+pNXobvKKuNwB9ax12yKQTkHqx45oVyq/Ij7V65OMUjR0rm/byKAwZFYOwAPfPtUkUxSUhR0z8rdR7VnWcyyKxPQYPUj8qs3ixyAoSrruBBGRyOhoMZQs7GvZTruLtknHGOcVopMrqFBJ9B6/jXLLLtK/MwI6ZrXtpxInzEAjnHYUjlq0y6XJViMA9Ao71BcMDgADn1FOaZCpxjI9Kq7w38Qz+dFiIxBImLbiRhe1SKAQQuOPWlgYlj1P1pywhWJJwxHIoKb7kkC8YbBFVdQiQgkjJq0H2kLwBxz6VSv7gJMFyWBHHHWgKabkV4Ld1IdH8txyGHXpWbNbrbPhc9PSryXpC7VHHqKzrh1kclieKR201K+pUmXdIW54Bx6Gs25LeWwXIGefQ10sFi0kJYcc8YrPvLPYxDLyOvHDUNHRTqxTsc3cSOkwCHAHXirtq5uYF9f50tzG6gROpMRYMMY6j1NX7VVXBUAfSs4wd2zoqVVy6IzLqIlWGCFP8XpVa3XarpkEjoSa6G/hE0e6NgGx09awJodrgMSCeOO9KcLO4qdTnjYapYccDHcU9Z+MMxyx4IqB2OzYuT6g9vc1R8xSzENgqeB6mlGVgnSUlqWZVElwrEkNnpWN4pnVo44Y2G3pj0q1c3GxhGCSQcnJ6Vyviu+GI0B+dh19K0lUST7nBUpy3Zw+ovsglRs5ZtvI7ZrOgOGq1rNwZmiVuqjk+vNU4D8wwa57aHBN3kexfD2C1s7NH23bXMtmbtmjnKK2D90KPQDrXc6gVWRWiWRLdkWVFLbuo6/XNcH4DaKytdMae9vGkdGnijiVSkYYkEZPUnHI6V2Wo3KXk5lEjupUA7wAc+mBwBWsF7pDfvHoDuQGL52n8vUUsUiZZW5BGQ23kfhVPzsNheg5K55PFSpJITkMoUryKyZ2pWVjTjSNI8HI3HG8jrTSFGWONmOHPXNVoeV3JJnjOG5qdcSLvUnAO3DDpn+tMS0FcqytjiNvlA7A4/lXmWrBo76V5sB0JiwO/vXpdyN+0jahxkEHg1534ttpLXXlztMLYkBJ4OTk0PY6cPLUqWsQCbjnB6A9fxq6JNrIuW5IwB0FVLKTJ8yQn5j1NW4I1kk3nGMdu9Uo9ju5luy9ENx+bt1rYsrczhSAD161jwOsr7FwV6YFdPYSJarGvA9K1jY5cRNxVluX7SxVGzLyw/KtERoQrKMc9MYzUUOJCxYkkjmrse1FHAHtVHjVJtvUFUBMdDVK6tYpCDIoJ7E1daUL8oOc+1QPyDtAOOKCY8yd0Yt2ojJAAA6A1mM3yAk5wafr91JG4EX5CqVrcGSPpyeCB60ubWx6lOm1DmZpWzO0gAUsoGQB61rRuVjBfCnvntWdphBdgcjIrQuLcyqhUn5WGcdSO+PeqZz1GnKzGxKs0rsTzx07VDPbIJ4laYRDu+M0acs8DyPNGQCeA3pTdRcGQeoJJHpQCupWWxTtXLM3mICDxj1FaqWkV1JC1w7v5ahEBbIVR0A9qy7Z1idndCc9MdatrdESI23EbHlfaixVVO+g+8sHjaSWKRCpOPcVkNuQ7SQWXrg9a6GcCS3wHIz0Getc5fAiVtvQDrTQUG3oxC+cBTjPU4rOuWX5mwQoPJ71YaYscHOMYA6ZqKUDzAzkrHnBPU49RSbO2EbFYunyAEnr8vTA9ajDidgVZgOgT1+vtSuBLHKQkhtFcjzHxn1Gfwpts2xAvBGN2CDlR6Cs+a50cti3ExGA2RjuOQKsxz4AGW2g8Y7VFDI8e3y8/vCSExzjHUmpQoIRmxliR154/lVJmLiT79yhwA49B3HrS6fJIkgMnryOwqvCjEjYvVcn2FWYlbA7Y/WmZSirNG+kCyR+qjnIPBpGt9rDGB7VNayIVCx84UZOMYPcUjXMSylZ1YrgkhDyPzpnnXlexTkS4WQBAxT2NTT3MduOuZFAxt55q3GyFGYnqO4rnLpreQXEdwsguPMUxyIeAOcg/Wk2+hrSiqr1Ww+a7aWXdnLscjFQyAzz7jMsICE72zjjkD8aIlbYWABA7imSbtp29/Wjc6oxs9Btrl4wzgj2PWp4LJJJp2kgeVmjxEd2Aj56n14qvbMWIRhtxz14roNMAAAJ5+tFhVpuGqLOj2TwW6rKAM81DrNpG0e4j7vpW1CQUAqC6QMCuM8c0HmKq3PmODvraKNj/EDz1qjFKI34wM85NdFq+nBH8yIEjGCPSuengC5JGRnp6Uz1aM1KO46SdV6Csa9kV3O7d1Cg5q7KWizwCO59Kz7+RJF3lSo7HHGazkdVJKIwMoYeccZBHWsa4QoXcYPPGavynbGe/ABJ5IrKu3GJAJNrLypI61jLY3Wmpn3lx+8G8g4AJIrktXdnvp953HPGa2NTciKRos4PUE85rmr6beRIW+VutQm3ucOJkkc/fZF1IrEHaccdKbCcOPSo5m3yyH1NT6dLFDdxSzwLcRKctEzFQ49MjmtXojxr6nsngSS8TRdONhc6fBAIiZY5HTeX3HLc+oxx7V019JO8qiZoHZVXLxEbSPw46VwfhLUNNkAK6Fap6nznP8AWu1e+SYKyQxxRgj9ygyuenOfWtIK0UTfU7dnRiBuOccH0/8ArVdhfAOV3HsR2rOjBLlvl345B4qZRhVy2M9QTgfnXOejoaEIJk3JlsdgenersbYyXXZzzt6fU1mgMrLtYBTxjv7VaRi20y/dyNxHJI+lFxMdK6NKinIyx6dMfWuT8fWBkSyu45Mx7jG+fzHNdhLNAzYdRx0XHJHrUV/aQ3tnNA8WdykDPBHHBFP1Lpz5WmeYlcbEGSvY+tXBJj7v3Aex6+1Z8sEtuSWOMMQAT1H9DVuxY+T8/JPzZI9apM9KLT1NK2d0jZol2uTwT61r6erxASOzSPnOD2rJs5VUqBjIP14rYgRnJ2sBzW0V1Mqj3R0GlyM+XlJyeRV673vFlX2lefm/i9qzbUGABpemPWmX+p7XWOPPPc+lU9Dy/ZOc/dNFZ2Uckbu3NT+W5iDOOvIqnpYErCWQYCc5961FmWY7eeOlBlUVnZHOajaOz78Dj1rP8rYR5YPHXPaumv5EhQucZ9KyVeOQEqAWb36UHTSqNx2Ft0kxiDGV/Wtm2dvLUHrjms3IXaobDewqvfXFzE8aR7cEckNjHuf8aHojKUHUlY2pXyGUqCPesm+gMJEmB5fp1qPS717pMSKRjqK2ZolkgKuAUYflQndC/gyszlnu41IZsorE4ZhhTjrg1YV1aMOjZQgFSDVi5SGe1S1mhLeQzMDu9evFUrhtkYMSnA4z6UK63OxWlsbFlL55CkZYdB3rK1ZCkrKqjbktuPb2qK3nuLOeN7iJojIu9N45IPGamvnDaa92x3MZRFgDtjOc/wBKXMmrkqlKE/Ix0G1jl8H164ppjaTkkKp656UrkuxbI2cL/wDqFTXbmVIjFEkQRSrKufnPqfei529ijKjNK3mMfKDHAAyW/wDrVae3QWEEhux5khJkjK8x8/KPfPt0qIv9nUXM21lhO5tw4x9O4qOBZHkMsjpjcSpX+HJzjFR1L32exLC67lMpaNySwZTk8dPpVqcEEB0CSMM8Hgt9O3FRK7Q+arsAjjOCuT07elSOZJUiMzfM8Yxkcbe3NMhjQ7Lt2uQp6YOD9PpV+0kXBB29AM9+KypMtwzEHoBj/PFKki5ZQ21yMgepHXmmnYcqfMtDoILk27ZUhiwII6j/APXWja2/28mSKJnZeCVGcHHSubtpjkCQHB6DPGcVOLtrYsEkdAeSFPWqOKdB303NLU5pLYiEnaccDuPrWPM2WyXA3Hk9afcTvOA8547k8k+9VkkDjB+XkFSPUUXLpUuVal6G4JQxoRsHU4pHy5+XA7fSo5rh5LiSe4k82VzlmAAyaeH+UHHyHnNCG421GrEEJLEbV6GrmmXZaXYTkg9vSmwosigdjyafGscDZQAN+VDV2ZzakmmtToYZ8fKBnAx+NSSsCmByT3FY6XJ8vMfBzxkU+SeRoslgB1GKDhdF3JZMZw2D9a5/WLdEcyLwDwQKqvJfNeDYrZ3cntirWoSEDEnGaSl0Z1xpOlJamBch1TaBnPY1i3JligCoueTkH1rpZUVkyOe2fSsTULaXzQUc89QaJK60O+nNJ2Zl4VoyXXP97HY+tZF/F5kxLYAA4yegrdkglYtGqjjGR0zWDqAKTA8HbgAHoR71jKGmpoql3dGFqW5R8oBKj061iyRQSQS+cvIB4zjHHWtu+LRu8nIzyRj+Vct4ycJFaCNmVpQSyjuB0pRi1qzzsVNWOWGMnHTsas2DQpdRNcxNNCDl41faWHoD2qqTk5p6feFNnmJ3PV/C1nBdWkdzY6BftAxwr/axg+vYZ5ro7vFtdmHyXtSFXMbvvK8dyP5VxfhbUIZU05ZftKqbZ9PlKoSqnOVdCOpyRkda6vUJoZb8iEzMkcaJI8w2s7qMFj3px2DqeoqCF2kZVuc9s0o4XgFl6Hd1/wD1VVgfCnJ46qtTxP0LMGJ9Dk1mdyuXLckA5clT82Bxj3q/b7UPysVbHc9fas1dj52HDe3XpVm3OcHhwM8460hl5XCgKB90Z+bGM+1WLeISuD64ABPeq0PlgxowHJ79j6fSp1ZcBnQqc8YNNEN9DkvHWiM6ve2y8glph6H1H9a5i2l42SEgFcfL1zXps+WSRZUDIwO7nPH0rynxBG2nTywgEYPGPTsaa0u0d2Gm5LkZp6XgzLsLFn/vDFdNbyRoQxIOOMf1rjtImKQrMT+8PAHt61prMTOmGCqp+ZRWsJWib1Ic78jp3mEjYDfKTzVgrHcSoPLUFfT+I+9YNvMJX2R7mJ5z0res9kbqruPNPJOa0TuclSPJsdBBEFtPLX5RjA9c0sFv5GSWJPvUSTlCQOSOvFKZmcMCp56ZoPOs7mVr0wZghGQe461mWMaRl2iZiOwPatl1TfmQ59jVW4aPdleMenFJKx3U5JQ5URKC8mOcHvWllVXJC7gMZPXHpmspphFl85GOo61JDc+fDnjNO5FSm373QnaeOOUjCg9c+tWY9RjKZByelYMrBUdpAQQSQw7irOmpBMwZ88nJCnGaNxSoxS5mT37DzdwBUkc+9MQgRhwUBTG1SPvH1q3qcaPArKp3J2HcdxVHahkf7M0nlDoJOv40wpy5oiakZb+7+1XTgy7AvPQ4GMfgKrSI5gMEcypC7BimcDPrUzSiZioOduAWY9PanS8gBlVgcgEHHNBtGTVkZczorgtGuB8oHqfUe9SR2clzsCcox5ycDnvQ0OJvkUucFcnuD6VMgKqFJ+XGMZ4Htmpsb82mhnXEZLYZd0SEgLyR7kU0Kd+clAThjnjH071ryRRsmC6kduMGqc1vtxyTgckdCPajlLjUT0K9rcKks2GUhlwNyZB56irlvEfIIU9QHIHIbH8qzy2wyLuYLkdun0q/ZSMY8HCEHaeegqSp7XRFNkgkAY9MVReVDIVfBOOo649q1HAmyBkg+/JrO1JFa4tnCKGRAHdRjdz3pSv0LpWejJ7eRh8rYkQEspz0qyW3jAHynkHFZ28gc/KA/Q9SfrVtrecEJM4RX+YGTKqR2Oe9CYpx7kb3AP8Aq+WXOR1AqMPsQbgwPTn1olAhvVa3ZZItodWOMnjocVG8jNM0ix7OSdqsWyD7mlctRSLSvbS206zh/M2jyWQj5WBGc+xFTW0zSEhcL2Oazm2hCdpVP4tvXnvT4JiiZ/jIwCSATQnYmULrQ6WIbIckgn+dQ3rHYWAZgOx9aoWN00sCs27eex7Vex5ybTnGa1Turo4XBwlqVbW4ebegQqw5Uegq2sjBQM5HUjtTYVjjc7Sdx4z61Idp3HkAGlFW3CVpbItJMrYz19Kq6hF9piwSAR0PtVYzqDz26YpRcqwJU59zVGfsmnzIx4rY28jDcxB4wTUd4Sr4RQW7g1eu5Rktnj6ZrF1GYkFtpLAdAcY96WkTqV5u7KqarFp1zdNcWgnFxA0MRLY8pzjDD3GK5LVXMhZ2zvcgDB61u6p5RgBJw2c5HrXK65c7Y0AHKHIxWMu7DRfCivrEpNkyFSGXBFeaapdSXV0zytnb8ij0Ar0C6umkiGBn69PpXnWoKEvp0XoHNNu7PMxRXzT065zTKs6fNNbXcU1sxSZDlWwDg/Q0nsci3O+0L7NqWmaan9pxWT2kfltBMGA3bifMUqOSeM9+K626uIZ7gTxymURxpEZXXBmZRgsR7msbw5LLp+j6f52uS2vmR7ltxaiTYuTyT6Gui1KxlKyXP25buWNIzJmPyzsb7jDsR2prYZ3Sxc5IwoPINSo5MgQKfQHpimzZbGew4XpTPNKzLuYjbx071kz0FqWkdkZlBGG5yOg+lXYJUdgu4nn86zG+YrhhkdFzU4EgIYKwGNuRSGbSS4XYR6Hn0q7DcLIiIVX5Sep6j/GsaAybA/Axkg+mOoNWojE64bAkz1A4x/nFMza7mhNCZEw7Mny8fQGuM8caBLeobtWZmi+WZQOWUdCK6xJM5RCwUnO5vyqyY2cksg9GYd/RcUblQqODueQ24WKCLOVIH3fT8as2UqzXIAHGeo6Vt+JPDb6fbS3Vsu+1UlmXHKc/yzXOWJUGLIy+ee3FUtz1KVRVI3R12lQrHIFGdzfxe1a1mIrl7kefHG0KbgshwXOeg96xNJuSdwIxj+dbZaOCJCk0TtKA7Io+ZCD0Poa26aHNUT5nfc2rLA2s3O0bjn+VMvtRgjWQLIyHsNo59qqRTkWfzbhuO7cRx9BWYY7e6mt4fNNtPJIQ88p/dKvbPfr3pSlbYwpUE5OUi0FeQO685HHvVAm4RufmUnbjuK1LSMD92ZY5CpwWQ5HXsaluU2qysOTz9abNlNRdrGRuMkhGcYGKZJdeTkFNq+uO1TSKqufMAwenamXEazpsYYI/lSfkbWTtfYbDN58QJGQ3Qd/pVhcKo8sgEHpWcqeRGVLZzVWO/kSaNJUAUucY4wKFK243Qc78mx0qXqKNkgbdisxiHkmfzNqhSyDGdzeh9KspAt8qb2IcDgqeRS3Nj9liTY7NzznrVas5I8sXbqRWgeeDLr8wGcVWu0uEfeCpBIwR2HfNXIG+YbSAT+FaMlrHLBuB5A7nihxH7TklczIixSM98cEHpQXz1Cqp6jH9KY7yW8ieZC22TO1vUCmybGyZMqOuF6mmmirdyw8iR2juJA8xYDy8YyPXPtVeSZYyCxb6A1nb23sMDbn5Mjr9aaJowV+0h2jDEt5ZGcdsCk5G6o2H3W15BnmMDIKcnPp9ansbmFcJef6uUACUg/u+eTgferNhn3cRHYw5X1pxR7qQRW4zITj5j+tTc25dOVmm7qd4iLhQcZP8XuPaq10sflJ8rF2PzeoPHWrFysjoHgXEQKqzLkgNjoffrTXL2aRzR3I3sXRhEQWXpnd25z1pMmO+jKWQEIwQTww6gH1NOgknuLhmdiwC4QAYUADHSoogyMGXlieQwyMn1qW6821nltndHeP5XeM5DH69/Sg1euhHJhGyAVyeo7evFNMjfKu44zjbjHFMsoJJm8teGJxuLcVLNayQqZJMqN23J7jtT3Q7pPlbGRNyDuJA7GrCqjoxlA2Dkmq0RWNWJUCM8HNWoWjLbFG4Z7Uk+hMu6LdoV2naPkqz9q8xCqHGDg+lVHmjiRVZQWP8IqaykgmlaOI5HcCnzWdrnPKGjk0WLZCspZj8p5xUF9OI24zt9q0YRGAUUAkcE1marEPm/unqO9W9jODUp6lRbremAQvPIPeq/wBqwyDd95ulVmKrKMdNvBP60pKhHIxuH51mnfQ63TSG314scboFYuSNpB6Cs+Vt0Zck72GPwqXzkzvI5A5qjcyoFdi3yHP4U92Q3ZWSM/UZsxZyMxnkeorjtechF3EAZx+db91cgNJwSDXK61PutmZtvyZGD+tTO0jmqysrM5+71S5sV8qCTaz569veufY5bJz+NOllaWRnc5LHJNMJpJWVjxqkuZ3Ac8VatELSDHaqyDdwa3NItw7ruOAO/alvoQeh+F4I20azfV008wKpW3NyXWTZn/Y/hznGa2r+7u4xcWt1FbB5GQuycqIwPkCkfwd6xdPubSWwtYtRguvNt02LJbso3xg5GQfr1FXtWZ5bmOQwmFPIQQxht2I8fLk+versNHpkmWyHycVEHBUjknucU85BAYbVGeaiHLAuCF6DArKS1O+Duh0Jyf3ZIHViw5qWEgFtzNt68d6gztcEFtpODxyafuBLbWAIOMevtUs0NBX8onL7ovWrsFznCMCvPA7kVlw7vL3MUwwwfX61LbXBwBjefu9Km4mrmwrF4flDbFxu46Vajf5GZS+/POTx9fas6KR5eMlBjGen+eatQzgI3y7Djucg4ql3JaLd8n2/Sbu2QeW00RRWPQE15BfWV3pd15FyrpLGcfX0r17znD8gEjoMfLj2FZfifQE1q2SQbRdxptUx/wAWOxzTtc2w9X2Tt0OSS8EMabWG/hiM9au2UVzc21zqYCRWsGN7O2Nxz90erd8VzsSiykkgvA6XeQQHU5IPfmrtxdTfZ/smSLctv8oN8pboD9cVbm9z0IxT2Oin1INpm5G4U4AzwKltI0nMEdxKtush+Zm6oM4yy9vpWDsmsi1rqUTwyxsC0bDkcAjP4Vv2lw99HdQxiGQIBcySyNiQgcYB78Y4obu73FKCivd+86+HRbS1bzbS786IpvAlTaWUdSvqM4rK1+6aLfEp+QrhnkAJA68Y6VQa9C2EEcRlYg5K5yCc8bRVjXrW6gtMX0DLvTfhhyF9xV9DjhTamnNmP9pXzvLYHdt3DcO3Y0j3Ajkck/gKilvDdXFobx0GweW0wHzsvQZ+g6Vj3jyRaiRGwljJwJB0YZ7is3UaPUhRUtH2NpiZZR/FkflUkMMUk2XAJHNZF3NKvzRPnooI4zUlpeyxTItxGyuDsYkc59/Smpq9mTKjLlvFm95nkksi4PY9KV71riPBIxnmoWkUp8x+XGSetVHYIm+Ehi3bNauVjiVFPW2pZlLRruTaeeRWjFJ5sIZX24GMdR/+usZJRPEwUHzF6Z6f/XqCK5ZQyzsocnHHHNL2g3QclbqjoLyNNiMDkjg81zmpvNGzNDsAHPznr6AVet43UPmTIYcDrtqldzbiIwrAKBy53Zbvz6USbsOjT5JdyL7QjRZaM+aR1zUErGOIkEBgMDFV7qYQ9ehIO7OCB3//AFUGXGODImcEjvUc19Dr5LaohLOz/c+8OMcZPr7VPbzLHI6yMwVvlOed1QyN5mZGU5AAz0xTZS2ERRlwCOmfwpLS7Kkr6NGzBfXEFrLbQ7PIm5YMu7Yem5fQ44zVYKoRgkjYBy2OKrxSs0arxlQPunORVqHbM3H05PX8KtO5ko8uo2DzJHCiN1Q9Oev1qd1CYZwF9FFSxxrtaOOXB9uTipIrQSQBfmIB/j7fSjXYTkr3ehQWBg7NHKQp5AXsfanT3MjgJMx8teuB3q5PGLeH5IyeeT6VAxDx7mj2Nj7p70XS0KTv7xWeJHiZS2FJyMnk+tMDxwxYDE+w5zVW5SR7jcmSpGM5xipYwhIjLZcYwB/OsnLU6fZ6GjpdzuvEuJoIpkhIOyTIVv8AZNa+lWayTSyjaCzF2C8BR6fSsXUYZFWFXDxsw81ScYcZ6/p0NdF4ftgbKQu4HAIBb5j9BTpvWzOLFNKHMnuIVHmkBiPRaztQkYnYFJGeTWlfqsLfu2J57mse+uCqfJ8z8966Gc9JXdzDvYxDcZDHdnp2FVLnUTDGflDM4xuA5A74qa+fLuZDt5BPPIrMdwAQ+Qynb0rB9bHo2011Ftme6YpBt3FSxLttHAz1P0rNnlDbUJY7vmwe34VYciT5AAvrWdqRaOQEkFgM5HapimtzCrNLQzNZlW1mDblOegzniuC1y/aR5IUzh23MfbsK1NY1GRUeaQBnyVVSeAf/AK1cmWLOzMcsTkn1pp3dzx8XVb91EZ4o68UpHNOVSSAB1p3OHlZLbxlm4Geldl4btYzNELpnSNj/AMs1DMPoDWBpdqWbhT7nFdz4csHuH8uCMvIy5VV+9kelVBXYOxuC30FE+W61MN90nyFOD370ahcwXN2jWhlMSQJCfMABbaMZxTm0DVmDt9huDnqSOT9aguLSW0d47hPLn27irAA4PQ496vdiueiwzgjDk8989KdkHJzlT6cYquAsgxvAQDG4AnNPiO4uMHjsT096xOyL1JQOdvVup9qcgyDgnAP0OfemgZjyu1gO2aQMpA2qSfrUs1uTAFpBjJA6DpU4cK5ODtxjA/nmqwZVUBgcmpYW35Re/Bz0P41LRVy0S5Td5jAEZGf4ufWr9rIjNHv2sg4GOv4/jWdGcbdzDbnoT0NWkx0OQBznOMjtQlYL3RrQMY26qQeFyffpV9GZ2aQKE4yPqKxrdjsU5BQnkDrn3q75rRLhRvzntjBFWjKUWZnjPw6Nalju7dwLyGMICfuuucgGuHnt57dx526GUDnI5H0r0x5REVkUPtO3A7kDr171l+K7VdRszNDC8lxFkhVHzNGeT9SKLJnVQrum0nscBJcM0zxSsT5mCcnJ/OnMZYnCJ8ydMhu2az7sLDeMAxJ7FuvPNXbG4IGDtKgfXFRa+jPYjNJXWx09rcozIm4h+owcYPXNbGt63qF/DsuZBKfL8veepHvXDteqtwGTIPAJrfsNSgvkttOECrctMd1znJYNgBSPY1p7RLQwqUbNVLGZBd3Om3rAxrvKFCJkyAGHUD1x0NbDS6cmh28MELyXpbfLM/AUc4RfX3Jqvr01zcX0UWobTLbL5BO3DfKeN3qf6VY02ZLLUba4iMdzBEN7pKu0NxymP61FrGkpc0VO2u+nUgj+W3S6RELwzA/McqT1Ax36VV1Cea7vZriZhm4cvI+MZJ9PStGTSWg0+PUZXURXDn7PAerLjJP0HT3psv2dtMaQzhLlJADbMnBQ/wAQP9Kb2HGcb3WvT/gFeOaLyhGZPlPHXFLFEkJMzOxULnAHasuSCT7SjITg9FB6mr5lEX7uU/vMlWjI5XH8qfP3LdO3w9S5A6ToGtiVUHJB6mql9Gkk+ZWYDHAUDrViyaJQxjZTjsO1VZYGe4d9wCnoT/KqlsZwilJ62EF35OQj70Hc5yDVYXMs0gVvudiTg0SeZHKBE4EfVx1ANETxSSOuc4POen4VHM3o2bKkkm0hZ44witI6jPJXHWmLFuGEGVb04xUi7DuLKJDjAwen4U9XWMBUJyQSQB09BTvfUlxaViFoCigS55/Cnxwhzuj6gdB0Hap2UyOrPncO3Xb9KjCEnKlh8xGRxVEtXIFjCPtQBQOCB3xV4CNSBt4PT2qBtyyYPp1POallBztc8qRj0ApXsS43Llq6q4IGWPXAq6J48qS3HQjpWFGzZYMcFe44yKuWk2WJYYOM4BxmmpGdSiasq5z24z161jPcJO5ABDKec8VctbnzZcMGygyC1UtRXN2jAgRHLFgM9O2O9U2KjHllZkaXy2ttIBGstwwKqzjKIOnA7n3rMhT7LOsm/cVIKkeoNWrmJGkIJAjPDZydvvVeRN2zyypRDgMB94Z6/jWEldnZBJJpdToZ5zqt39tvUVp2xllXaD+A71bllMQXy8g8Y9vaqFocWykA4X7zdhUivNJvkt43l8lDLIV52qO5rqikkedOKbt0QXtyzcsc54+lYl1cYY9Nrdwale4DEsCpGefasS5IQ7VbOT1PGBUzl2NadNLRjribzHfC7sc59KyrpyGJBIGKluphAR8w29uazZbrB+ZsZ6j0FY819C5OyGy3IT94XC885rJ1/VIktvMeciPpkDJJ9B71T1vUwttJJIqnaedp688D8a4fU9SuNQlDXDAgfdReFX6CnBuzR5uLxCg7R3E1S8+23BdU2Lk4BOTVMcUd/enIuSKo8l66sFHOPWr9rakkZU+tPsrUtkkdBnNb9jafKq7SST0oSuK+pLpNnhSM9Oc4610kMZgVGjO1yvyleCDVTT7cJEPMBU5ArWiV4HjltnKyxfNnPKkfzFaJaCtdkt5NPfMbhhKko2rIAGAbtu+vHNU5S6xM02RJ0G4csK6aW+165dZ7SK9hV0wVCnaT/eHHQ+lc7qkss8jSTyPLLwD5g+YAcbT9KaQmeiJLti2g5J5AXpmjB7sQCKptIV5GSPTrU0T/ACllOMdVIrJHWi0rYAPC5GM/4UobamQeTn2wKrodxVdxZu3tVpFWRTyBjovqfUmpaLUrCxMBjbldx4z06U9XHJCg89BUIbaXyQTnkgcEe1OLA8ZG7I4Hp/8AWpFJ6ljcN6Zbbj75XmrLNl9jMu9Tw3XdWa3Dr+hNWIpWwq7RjnlxSKsaNtL5SMOTuODjoRV+3nQTAvEQgODk9FrJh4cDHy5OMdKtREkKpOMnBBPSiwbmooLx/LIGj3cqeoOfSrcFwJQsBTy/4S3ow/kKzMfdfI3nO5QOasQzZVfMUbG447ketNCaujP17wxZapL9qZ/LuVG0soGGPuK4G8h/sqRraSJw6kqXYYzXrEbQF1L5ERHLcn9Kq6rp1lqcJju4GaMDAcHDK3rmmbUsRKm1zao8w08RrC63CHLqDEwPfIotAkF6XY/l2rV1vRLrRwRZGS6s2GVJTLIa55LhmnHnKEGeRnmodla56tOp7RNxejOok1K8u4DHLcmaAvuw4BO7GM569KWO4t9xilULK5VY5C+Fj55Leox2qjDqS28M9tGIwZwCSyA/98ntVELuj3Eq8gOT6VUnbYqEb3VrHSJHH/bKWdncrMhlEcc0nyqwzweegz2rauljtHDSRtHqMLffYZBH0P41ykE9tc2sqyxbLjKlZAfu/wCeK3n1yW51FNRmVJZYwm9NuVfAAOR70RadzKpCV0ZckRE5KHBY8Kg6Htir1/YwnWSlwktiTsJD/Oy5AyWHfPUCqc19cm7aeGNbVkbdF5Yxs64z781p6Ra2up6e6sZ3115GlG85SUAZIzng8ZqdzScpQXMzKu7SJdYWGxuGktQ4DXHlEcZxnb+dWpdImutUawtZVmmLERknYG468ngVBpi3l1DevZrMsEUf+kFDkBSeQau6RYz6pPHYwXdrGFAcMzggbjgDPUnPamolTnKN25bL+rmS8U1vBPvEZZGwwz1Pt60yJFIAAIJ6DGa6FdKN5rUdrFBJawKu2eWX5grLkM/+7kHp6VD4r03TtLvLY6TfreI0QZ2TgK3r+NK3Uarxk1Dq9f8AhzCkgaOR0VXinDYYOOc/0oTZEhJLbs5+Uc1oS2kbaG2pPco87zbFhzuZs5yX7r7etJbG0j01/NWZrppAEIX5FTHJJ7nNC3NPaXWmvQppKTPhwecEe/rVplLs3lRk9Op4p1vbEuTEGdQu5gBnC56n0rqbPSbk2vnw2ztGF3ZC9B6mrimc9atGGpyE7MBh4tjr154+tNA3HDnnaK3daiRoS2ACPSsIKkp3GRUWMABT1b6U2rFU5qavsPZvLXbIBjPGOpqIo+TJtEijoWOP0qSSKIJmN8sQGxknOe31FQnzMlyx2ABTk/d/yKnYvpcmW6dThGG3+L3qO51GT+zvsD28IHmmXz1PzsfT6UuqXa3F3LOJC6ucGTywpbj+6OlZ/wArzDgAA5O7o1G41FPVomkBkUAknI+b1qCLEDFBxjjnqKRptkhJBAAIx6VUURLOS7McjhfehofTU17e5LZyeB0qfV7u3SGZdHurlYpMRujrt3IMH5vx7VSmksLexsXtrvzrmRT50Gzb5JB6Z78c1hT6gN5APLZxn+gqpSVtzBQ5pc1i00hYYRgCo5B6ms3UZXwyAqSvOM9KqLe/O5RiQec5qjfXX7rapRWY5PPJrLm0KlaOo+5nAGR+TY61hapqiwqWdtsecZ7t7Cqut6nFaLtLCWVuAgP6k1yF1cSXUxklOW6AdgPQU4q+rPLxWLS92O5LquoPf3DN9yIcKg6D3+tUWX8KftNTwwMSOK0PJd27shSPcRjnNaNlZFmAINWLOyZv4T7cV0lhpvyKNvL8/wD1qai2xEGn6cVkX5Tgnj61u21mp2gIQ+MfjmrVmjKnzHq3JPftitOCOMKVAI7ZPqa2UVYnZlFkbB3fK2No9OKtaXJHbX9tdyRuUjYO6kdfXr19aWWEhzk5jQ4b1qxaCAX9oZyoj8wBwSdo+p9CcUJDemgSIk8zPHr8BGSd7SvuwTkcdiKzfEN1FdXitDIZNqLHJM4wZGA5f8a055hcPPaayttBcYKxzRoE8tj0BxwUPT2rP8SK9tfxxOqfLaxfKMEEhcde/wDWmvMzZ2kjOqeWrKqnngYzTkcYGDz15HAqtgNKoLKceg4pwBHGcjPpWVzqvYsFt8Z2gL7k85qQOGVFGFXqahVAy7uQR3A4NP3HLcEseme3vmpZaLCurAgjnoMGiPAALbvfA6CodysAU4c9WJ59uKlcnyx5jk9zxk+1Qy4uxMH6N1559/rU4JaFhnrjA65/+vVKJyQVKqAO47VPbnDMQSPQAcUjQkiBVgJDtHPOe/8AjV2F+QCw2qcbfT3NUcMvJ5K9ARmrERXqo+UHoOtMdzRhk+T5QflPJq0HOCCqup59MVmrnkEYByevWrCsCNwDbcdPSgLF2KeZVA2qynkjPOR1qYzL5m9X82MYBBGDgVRgmXcXAIzj3wameYRuw9SNy9z9KWoW1sXEmXzGdFbb/cYdV/8ArVy2reDbO/uTLE4s5G5PPyP+HauhEzsydEByNx7qaerb5RbxEOgPynH50BFypu8WeZ6rpUlqskEiPGY+VZh8uPY+lQwSCO2jkkGYj8pYDv6/SvTL23iu1kEkfyngoR1Hoa5PUvCXlTsdMnCwsf8AUSk4/Aihrqd1HF6WmzBMke8hB1X5XX+L2q+l0xEbQMNyjBBGP1qjfWsunO0EiPC/UE4KH6GoobqQAmRAM9OnP40tjuUlNXjqbsEokViRnJxk0zy3mWQbggjGRzgnnGB71lwXgdG6qQM9KltrmVWbzGXB6EcmrbTBRavY2fD1wulymWKaaOUuASmD8v8AFlT1z+Var3mm32q3MEWnyedcTL5E4ZUdQFxtPYZOCTXJec/nAqRt9+lWbN0a7Hm5EQYFsdSM84qVawqlLmbm9z0CHQZlaS1vWil1WUrINkm2OCEfeORwc8g+nWqOkox1gQaLYC6mlVo3WcHyrfrkZ6HI71kajr62ur3B0IvbWhwsY6nb689zT9E8Z6vosMtvZSRFJHLkSpkhj1Oap2OT2VZxb3v0en9WKVvpxj1mS1vGt7Z4y28XP+rBA6ZH5CjUtTu7vyDcGMJCvlxpGgUYHc46n3rNuJ2ubiae4G6eVizEdye9R9RzuCdPcVOy0O7lu1KW51WhavZafNe74si5j8pVjOEww53E88Hmug0Px3LaWaWUkMM0EYMYJyNw9a8485cHcuMc+9L5xkzubKnknrVJ2OerhKdS7kjodXvI5SSvy7+cA1igx7yB8ozn8KrGQnJbP1J4pEkJBHG3PB702zSnDkVkWS6xOyKQyA8sB1qK5dQoOVYZ6AdRUJmxwQG+i8U5mP2faeQTnFIu+qI5JFYjPQfhTG+4xQrtJzg+1V2YNkYB561BcSCNOpAPYUA2SyzASDgFaqtKokbA2jsaryXPmKQv8PXFZ890AobqSccmpk9BPTctPcKiyZHrlayLtiU4JAY8DPantO8hJKh2HP0rJ1fWba0O2YCWU9I4j0+vpUuKaOepiVTWrHXMyxYJI28E/wD665vVda+7FaEOFJJkIyPoPpVPUNRnvsqcJEf4FP8AM1UEJJ9/WiKUTyq+KlUfu7EErPLIzyEszdSe9AiJIwOK0IbNmYADJNaVvprFgAOpx9KtXexx2Mu2sy5BbpW3Y6X5jIoUZPrWtYaXwpIH0PrXQafp4WTnbtz90/54rWMO4jKsNM2x8ABt2NpHI/8ArVswWoBCtgIMn6Z96vpbhG4IbcCpH61NhFEbMOGOSfYf0rS1gsyjHAyhRJng4xjpV5k8rHl8r2Hp9fWl3NHIrfgCegz2PrUYJdcqu11B+Xs3rihPUJJlad8ODKOM7crxmqN1veYGNiHJ2HvnPTp+VWpGYBTkBic8Hr6imaVcLDqUTSskQDbNzLwhIIBP0OKCJbEM1gYVERurSO5HymJn/wDHScbQfqayZEmQzwzqUZW5RmwFYdvb+VdJMyR6jCrusYRBFJaGMvJkDlQuPm3HPzZxzmue17yze+T5il44Y4pCefnA5Ge+OB+FUnqZs9Ec7ZcLwrEgj6U9yMYAOPQmiisUdQJ8oCg8VIzMxC5wCe1FFJlk8fyblGMZxnHNLL8jFR35J7miipkCI2AjSMrnLdcmr1uNwck9G249s0UVCNiwnGRgfdJzinqNmzBOG7fSiimBJExUgg85zUiu27g9TRRQy47liADn06Y/GrAw88YkUN2HtRRUsXUVCxkA3HC8AHnip4JA4MTLyhyHzz1ooqhzHGRioccFAF+uaSRRtjA/iPNFFNEEV3BbSxNHNbRSKrYG4Z6155rWmQwagYrcCNR8wwOntRRSkdGFk1LRmVqRa0ZApDZPp7VLbSHJz3xRRSW57EV7tyVT8xx0J6ZqbuACRjpjtRRSW4XJoRkDPrTJWKTcdNveiiq6FLdj1mZugClehqMysBnPXNFFAkNjlJbBAx6UPMWfhQoA6CiigljmlO1V7YzUQc5AHAzRRQxRGliB64yagkncBcH170UUIfUqyXTLuXHQetZ0l223JGTnuaKKkJbMzzdybmiTCqx571HeytHBJ0LIMg4x+XpRRTicVduxyWoa3eXbNHv8tBwdvU/jWf5YLAsSSepNFFSeRUd5E8NurEDOMmtK0sYyu45zRRTW5BtWdhGRkcY4xj0rZFhEkROAcdOKKK3iJGlZ2cYPuACDWjb28cgJI5xnP9KKK0BkifLFGcA5GefUUy4/csuzHIz0ooqQRT2gxjOevTPFJOu6DzT1BxgevrRRV9BSKeosGC/KoyueB0PqPSsqVsHOAdwywPOaKKHuZMiOqXwRrdLudIsEABzwB2z1rFumb5uRnPpRRSWxm9z/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple white plaques are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6506=[""].join("\n");
var outline_f6_22_6506=null;
var title_f6_22_6507="P-glycoprotein drugs";
var content_f6_22_6507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inhibitors of P-glycoprotein",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bepridil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diltiazem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketoconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propafenone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ritonavir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verapamil",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The drugs listed above cause elevations in serum digoxin concentrations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6507=[""].join("\n");
var outline_f6_22_6507=null;
var title_f6_22_6508="Nasal challenge protocol";
var content_f6_22_6508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nasal ketorolac and oral aspirin challenge protocol*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose of intranasal ketorolac (in sprays) or oral aspirin (in mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 am",
"       </td>",
"       <td>",
"        1 spray (1 in 1 nostril)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8:30 am",
"       </td>",
"       <td>",
"        2 sprays (1 in each nostril)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9 am",
"       </td>",
"       <td>",
"        4 sprays (2 in each nostril)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9:30 am",
"       </td>",
"       <td>",
"        6 sprays&bull; (3 in each nostril)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10:30 am",
"       </td>",
"       <td>",
"        60 mg of aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12 noon",
"       </td>",
"       <td>",
"        60 mg of aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1:30 pm",
"       </td>",
"       <td>",
"        Instructions and discharge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Day 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 am",
"       </td>",
"       <td>",
"        150 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11 am",
"       </td>",
"       <td>",
"        325 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 pm",
"       </td>",
"       <td>",
"        Instructions and discharge",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Clinical and objective evaluation performed every 30 minutes and as needed.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Provoking dose is repeated; symptoms are treated as indicated.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105:130. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6508=[""].join("\n");
var outline_f6_22_6508=null;
var title_f6_22_6509="Methanol metabolism";
var content_f6_22_6509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Methanol metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 239px; height: 425px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Blocked by ethanol and fomepizole.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6509=[""].join("\n");
var outline_f6_22_6509=null;
var title_f6_22_6510="Unconjugated bilirubin no anemia child";
var content_f6_22_6510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to the child with unconjugated hyperbilirubinemia who does not have anemia or hemolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mandl KD. Jaundice-Unconjugated Hyperbilirubinemia. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006.&nbsp;Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6510=[""].join("\n");
var outline_f6_22_6510=null;
var title_f6_22_6511="Vibrio on TCBS agar";
var content_f6_22_6511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vibrio species on TCBS agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vibrio species can be selectively recovered from stool by culture on thiosulfate-citrate-bile salts-sucrose (TCBS) agar. On this medium, V. parahaemolyticus usually produces a green colony and V. cholerae a yellow colony (indicative of the fermentation of sucrose).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_22_6511=[""].join("\n");
var outline_f6_22_6511=null;
